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     ABSTRACT      
 
High voltage-gated calcium (Ca2+) channels (CaV1 and CaV2) are essential for many 
physiological processes including muscle contraction, neurotransmission, and gene transcription. 
Despite divergent functions, these channel families share a conserved carboxy-tail (CI) element 
that has been shown to bind calmodulin (CaM) to afford dynamic Ca2+ feedback of cellular 
excitability in neurons and cardiac myocytes. Unfortunately, global inhibition of CaM 
indiscriminately alters numerous processes provoking unintended consequences. Furthermore, 
Ca2+-misregulation of channels underlies numerous maladies including cardiac arrhythmias, 
neurological and neuropsychiatric disorders, and skeletal myotonia. Thus, identifying pathways 
that individually adjust the gain of Ca2+-feedback is critical. Here, we demonstrate that a recently 
identified partner of CaV channels, SH3 and cysteine rich domain (stac), increases channel 
trafficking and channel gating independently from CaM. Moreover, stac exhibits remarkable 
selectivity in suppressing CaM regulation of CaV1 despite being presented with structurally 
similar targets. In all, these findings furnish insights into orthogonal control of CaV channels as 







 Though the fig tree does not bud 
  and there are no grapes on the vines, 
 though the olive crop fails 
  and the fields produce no food, 
 though there are no sheep in the pen 
  and no cattle in the stalls, 
 yet I will rejoice in the Lord, 
  I will be joyful in God my Savior. 
 The Sovereign Lord is my strength; 
  he makes my feet like the feet of a deer, 
  he enables me to tread on the heights. 
 
Habakkuk 3:17-19  
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     CHAPTER 1      
Introduction 
 
 In the current age of information and technology, most people, young and old, find it 
difficult to survive without electricity whether it is for work or for pleasure. Similarly, the human 
body is unable to maintain life without its own set of electrical signals. In biology, these electrical 
signals are generated by a careful balance of ions inside and outside the cell regulated by 
specialized proteins known as ion channels. While there are active and passive ion transporters 
where the general distinction lies in whether or not ion transport requires energy to be expended, 
this dissertation focuses on the regulation of a class of passive ion transporters known as high 
voltage-activated calcium (Ca2+) ion channels. 
 The ion Ca2+ first came to the forefront of science in the 1880s when Sydney Ringer 
reported it was not important for cardiac muscle contraction then retracted this result and supported 
the exact opposite sentiment in a series of papers to the Journal of Physiology (Ringer, 1882). 
Despite its misunderstood beginning, Ca2+ captured the attention of many scientists and is now 
known to be involved in many physiological processes including muscle contraction, 
neurotransmission, gene transcription, inflammation, cell motility, cell growth, and cell death 
(Berridge et al., 2000; Clapham, 2007; Giorgi et al., 2018; Maier and Bers, 2002). Ca2+ influx 
through the membrane not only causes electrical excitability but also acts as an activator of 
different Ca2+ sensors that initiate downstream processes including calmodulin (CaM), troponin C, 
S100 proteins, protein kinases, and protease calpains (Carafoli and Krebs, 2016).  
 Given Ca2+’s powerful and dramatic spectrum of influence in biological processes, 
meticulous regulation of this precious metallic ion is necessary to ensure life. The past few decades 
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of voltage-gated Ca2+ channel research has identified four such important members of the L-type 
family and three members in the P/Q-, N-, and R-type families (Figure 1.1A). These channels have 
been found to be expressed in a variety of cell types including skeletal (CaV1.1) and cardiac muscle 
(CaV1.2 and CaV1.3), inner hair cells (CaV1.3), retina (CaV1.4), brain and nervous system (CaV1.3 
and CaV2), and even in the pancreas (CaV1.3) (Zamponi et al., 2015).  
 Physiologically, Ca2+-regulation of CaV1 is critical for skeletal muscle contraction 
(Bannister and Beam, 2013; Schneider and Chandler, 1973), cardiac electrical stability (Limpitikul 
et al., 2014; Mahajan et al., 2008), rhythmicity of oscillatory neurons (Chan et al., 2007; Huang et 
al., 2012), and vesicle release at ribbon synapses (Joiner and Lee, 2015), while CaV2 modulation 
contributes to short-term synaptic plasticity and spatial learning (Adams et al., 2010; Jackman and 
Regehr, 2017; Nanou et al., 2016). As a result, aberrant channel regulation underlies numerous 
maladies including cardiac arrhythmias (Venetucci et al., 2012; Zimmer and Surber, 2008), 
neurological and neuropsychiatric disorders (Adams and Snutch, 2007; Striessnig et al., 2010; 
Zamponi, 2016), and skeletal myotonia (Cannon, 2015). 
 Structurally, these channels are very similar. They contain four homologous domains 
covalently linked to one another by intracellular loops to form a “hole” in the membrane and are 
typically referred to as the pore-forming α1-subunit (Figure 1.1B). Each domain contains six 
transmembrane segments. Transmembrane segment four (S4) is the voltage sensor generally 
encoded by a combination of four positively charged amino acids (arginines and lysines), and the 
extracellular loop between S5 and S6 forms the pore domain that distinguishes Ca2+ from other 
ions in solution to selectively allow its passage through the channel. Upon voltage depolarization, 
the positive charges in S4 moves and changes the conformation of the pore domain to a permissive 
conformation (Lacinova, 2005). 
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 Remarkably, the biophysical properties of how these ion channels behave under electrical 
stimulation may be elementarily captured by the following simple equation: 
                        𝐼(𝑉) = 𝑖(𝑉) ∗ 𝑁 ∗ 𝑃𝑂(𝑉)                                         (1.1) 
where V is the voltage stimulus, I is the total current passed through the membrane at V, i is unitary 
current according to the Goldman-Hodgkin-Katz equation at V, N is total number of channels in 
the membrane, and PO is the open probability or likelihood for channel opening at V. Subsequently, 
proteins that interact with channels modulate one of these properties. 
 One example of this modulation is with auxiliary subunits. β-subunits are believed to bind 
to the intracellular loop between domain I and domain II (I-II loop) to increase surface membrane 
expression thus increasing N (Fang and Colecraft, 2011; Weiss and Zamponi, 2017). On the other 
hand, γ-subunits are thought to reduce expression and decrease N (Freise et al., 2000; Polster et al., 
2016). Similarly, α2δ has been reported to increase number of channels on the plasma membrane 
as well as PO (Weiss and Zamponi, 2017). 
 Another example is the Ca2+-binding protein CaM. Though it remains controversial in the 
skeletal muscle, CaM has emerged as a dynamic regulator of neuronal and cardiac Ca2+ channels 
(Ben-Johny et al., 2015; Halling et al., 2006; Minor and Findeisen, 2010). The binding of CaM to 
the conserved carboxy-tail element, termed Ca2+-inactivating (CI) module (Figure 1.1C), provides 
negative or positive feedback to the channel known as Ca2+-dependent inhibition (CDI) and Ca2+-
dependent facilitation (CDF) respectively (Ben-Johny et al., 2015; Catterall et al., 2017; Minor 
and Findeisen, 2010; Saimi and Kung, 2002). Thus, depending on whether the binding occurs with 
the Ca2+-free CaM (apoCaM) or Ca2+-bound CaM (Ca2+-CaM) the channel will exhibit an 
upregulation of the baseline open probability or relief of this initial enhancement manifesting as 
Ca2+-dependent inactivation (CDI) (Adams et al., 2014).  
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 Unfortunately, CaM regulation of CaV presents two sets of complications. First, the high 
sequence homology of the CI region poses a daunting challenge – mechanisms that tune 
Ca2+/CaM-feedback must distinguish between structurally-similar targets. Second, CaM itself 
regulates an abundance of proteins performing vastly different functions (Marshall et al., 2015; 
Saimi and Kung, 2002). Not surprisingly, global inhibition of CaM alters numerous processes 
provoking unintended consequences (Persechini and Stemmer, 2002). In this regard, identifying 
pathways that individually adjust the gain of Ca2+-feedback is critical. 
Recently, Src homology 3 (SH3) and cysteine-rich domain (C1) proteins (stac) have been 
presented as attractive candidates for modulating CaV trafficking and gating (Polster et al., 2015; 
Rzhepetskyy et al., 2016; Suzuki et al., 1996). Initially found in various areas of the brain, stac 
became a protein of interest for CaV when it was first identified as a component of the excitation-
contraction (EC) coupling machinery in association with debilitating congenital human 
myopathies (Grzybowski et al., 2017; Horstick et al., 2013; Nelson et al., 2013; Stamm et al., 2008). 
An autosomal-recessive disease was identified in a culturally-isolated population of Native 
Americans (Stamm et al., 2008), but has since been observed in Middle Eastern, African, and 
South American individuals (Grzybowski et al., 2017; Telegrafi et al., 2017). Patients present with 
symptoms of muscle weakness including short stature, kyphoscoliosis, talipes deformities, and 
drooping facial features and increased susceptibility to malignant hyperthermia (Grzybowski et al., 
2017; Stamm et al., 2008; Telegrafi et al., 2017). Stac3 has been shown to abet plasmalemmal 
trafficking of CaV1.1, the voltage-gated Ca2+ responsible for EC coupling in skeletal muscle 
(Horstick et al., 2013; Linsley et al., 2017a; Polster et al., 2015). Functionally, homozygous KO 
of stac3 in mouse and zebrafish models led to markedly diminished CaV1.1 surface-membrane 
trafficking, reduced tetrad formation, loss of retrograde-signaling, and a near-complete loss of EC 
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coupling (Horstick et al., 2013; Linsley et al., 2017a; Linsley et al., 2017b; Nelson et al., 2013; 
Polster et al., 2016; Polster et al., 2015). However, over-expression of a myopathy-associated 
mutant stac3 partially rescued channel trafficking though EC coupling remained reduced (Linsley 
et al., 2017a; Polster et al., 2016). In addition, the structural determinants of CaV1.1 that mediate 
stac binding also remain unknown (Campiglio and Flucher, 2017). Thus, stac3 may elicit multiple 
regulatory functions of CaV1.1 through direct interactions with the channel or mediated by other 
proteins (Linsley et al., 2017a; Polster et al., 2016).   
Interestingly, co-expression of stac with CaV1.2 was also shown to suppress CDI (Polster 
et al., 2015). Even so, the specificity of stac in tuning Ca2+-regulation of the broader CaV family, 
underlying molecular mechanisms, and their physiological functions remain to be fully elucidated 
(Wong King Yuen et al., 2017). Stac (Stac1-3) isoforms share a common architecture containing 
a C1 and two SH3 domains fused via a linker (Figure 1.2) and exhibit tissue-specific expression 
(Nelson et al., 2013; Suzuki et al., 1996). Stac1 and stac2 are expressed in various areas of the 
brain (Nelson et al., 2013; Suzuki et al., 1996), the peripheral nervous system (Legha et al., 2010), 
retina (Wilhelm et al., 2014), and hair cells in the inner ear (Cai et al., 2015), while stac3 is limited 
to the skeletal muscle (Nelson et al., 2013). Genomic and proteomic studies have also implicated 
stac in a variety of diseases including patent ductus arteriosus (Hsieh et al., 2014), periodontitis 
(Mizuno et al., 2011), cancer (Hardy et al., 2005; Mitra et al., 2010), erectile dysfunction, celiac 
disease, learning (Maciukiewicz et al., 2017), fat synthesis (Akiyama et al., 2015), and heart failure 
(di Salvo et al., 2015). In addition, biochemical studies have shown that stac interacts with other 
adapter proteins including poly[ADP-ribose] polymerase 2 (Troiani et al., 2011) and 14-3-3 
necessary for immune function (Satoh et al., 2006). 
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Given these complications and discrepancies in understanding, this dissertation goes far to 
resolve general mechanisms by which stac modulates trafficking and gating CaV channels as well 
as debates surrounding CaV1.1 CaM-regulation to reveal long-sought physiological insights 









Figure 1.1. Structural homology of voltage-gated Ca2+ channels. 
(A) Dendogram of the two sub-families of high-voltage activated Ca2+ channels.  
(B) Crystal structure of CaV1.1. Domain I through IV highlighted in blue, red, magenta, and yellow 
respectively. Black dashed circle indicates pore region (pdb: 5GJV). 
(C) Cartoon depiction of CaV1 and CaV2 with homologous CI region composed of two vestigial 




Figure 1.2. Stac isoforms possess conserved domains C1, similar to the cysteine rich domain found 
in protein kinase C, and SH3 domains. Fraction of homology comparison shown below for the 
three stac isoforms.  
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     CHAPTER 2      
Experimental Procedures 
 
This chapter summarizes the protocols used to interrogate the biophysical and 
physiological properties of Ca2+ and Na+ channels in relation to various modulatory proteins. 
Molecular biology – CaV1.1, CaV1.2, CaV1.3, CaV1.443*, CaV2.1, CaV2.2, CaV2.3, and 
NaV1.4 variants were unmodified from previously published constructs: CaV1.1 was a gift from 
Kurt Beam (Colorado), CaV1.2 (NM001136522) (Wei et al., 1991), CaV1.2-G12-CaMWT (Mori et 
al., 2004), CaV1.3Δ (AF370009.1), CaV1.3L engineered from CaV1.3Δ and human long distal 
carboxyl tail (NM000718) (Liu et al., 2010), RNA edited variant CaV1.3MQDY (Bazzazi et al., 2013; 
Huang et al., 2012), CaV1.443* was gifted from Dr. Soong Tuck Wah (National University of 
Singapore), CaV2.1 splice variant 37a(EFa) with 43+/44-/47− (Soong et al., 2002) was gifted from 
Dr. Terry Snutch (University of British Columbia), CaV2.2 (Jones et al., 1999), CaV2.3 (Mori et 
al., 2008), NaV1.4 (Trimmer et al., 1990). Stac variants were purchased from Origene: human stac1 
mRNA transcript 1 (NP003140.1), mouse stac2 (NP666140.1), and human stac3 isoform 2 
(NP659501.1). U-peptide was synthesized by Genscript (KVDPVYETLRYGTSLALMNRSS). 
Fhf variants were gifted from Dr. Gordon Tomaselli and Dr. Jeremy Nathans (Johns Hopkins 
University).  
RyR1 P2 domain was synthesized by Genscript (sequence in Supplementary Table 2.1). 
CaV1.1 CT chimeras were generated by first using PCR amplification with primers P01-P02 
(primers listed in Table 2.1) and restriction enzyme cutting sites XhoI and KpnI to generate a silent 
mutation to create a unique XbaI site ~1-2 amino acids upstream of the EF hand and add an MssI 
restriction enzyme cutting site. CaV1.3 CI region was added to this construct by PCR amplification 
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(P03-P04) and inserted via XbaI and MssI restriction enzyme cutting sites. For the CaV1.1 variant 
by PCR amplification (P05-P06) and cutting sites BglII/KpnI to insert an XbaI cutting site in place 
of the stop codon. Then, glycine-(12)-CaMWT was PCR amplified (P07-P08) and inserted into 
stop-less CaV1.1 with XbaI and KpnI. CaV1.1ΔCT was ordered from Genscript with the carboxy-tail 
truncated after residue 1397 (i.e. SILGPH*) and inserted with XhoI and KpnI. CaV1.1 (BBS) was 
generated by overlap PCR (P09-P12) and restriction enzyme sites SalI/XhoI to insert BBS. β2A-
glycine-(8)-CaMWT was unchanged from previously published rat β2A modifications (Yang et al., 
2014b). Using PCR amplification, we cloned CaM1234 (P08, P13) into NotI/BsrGI to generate β2A-
glycine-(8)-CaM1234. β2A-glycine-(12)-RyR1 P2 was generated from PCR amplification (P14-P15) 
and inserted into β2A-glycine-(32)-CaMWT from a previously published construct (Sang et al., 2016) 
with BsrGI and compatible ends NheI/XbaI. C1 of stac3 was PCR amplified (P16-P17) and cloned 
into pcDNA3 with NheI and BsrGI. NAM mutation was generated by QuikChange mutagenesis 
(P18-P19). Venus- and Cerulean-tagged constructs were generated by PCR amplification (P20-
P23) and inserted via NotI and XbaI restriction enzyme cutting sites into previously published 
constructs (Sang et al., 2016). All constructs were verified with DNA sequencing. 
Transfection of HEK293 cells – For whole-cell electrophysiology, HEK293 cells were 
cultured on glass coverslips in 10 cm dish and transfected using a calcium phosphate method 
(Peterson et al., 1999) with the following DNA combinations: 3 µg of SV40 T antigen to enhance 
expression, 2-8 µg of α1-subunit of Ca2+ or Na+ channel depending on expression, 8 µg from rat 
β2A (Perez-Reyes et al., 1992) (M80545) or β1A from mouse (NP112450.1), 8 µg from rat α2δ 
(Tomlinson et al., 1993)  (NM012919.2), and either 8 µg of CaM variants, 8 µg of the stac1, stac2, 
or stac3 variants indicated, or RyR1 P2 variants as indicated. Similarly, for bungarotoxin-labelling, 
HEK293 cells were cultured in 60 mm dishes and transfected by calcium phosphate precipitation. 
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DNA concentration used was half that for electrophysiology conditions. Drugs were purchased 
from Sigma. Nifedipine and diltiazem were diluted to 1 mM in dimethyl sulfoxide (DMSO) while 
verapamil, ranolazine, and mexiletine were diluted to 10 mM in DMSO before added to cell culture 
media. Cells were incubated in the respective concentration of drugs for 24 h before 
electrophysiology or bungarotoxin-labelling. 
For FRET-two hybrid experiments, HEK293 were cultured on glass-bottom dishes and 
transfected using a standard polyethylenimine protocol (Lambert et al., 1996). Epifluorescence 
was collected 1-2 days after transfection. 
Adult guinea pig ventricular myocyte isolation – Adult guinea pig ventricular myocytes 
(aGPVMs) were isolated from whole hearts of Hartley strain guinea pigs 3-4 weeks old (250-350g). 
Guinea pigs were anesthetized via intraperitoneal injection with pentobarbital (35 mg/kg). Hearts 
were then excised, and single ventricular myocytes were isolated following a previously published 
protocol (Joshi-Mukherjee et al., 2013). Cells were plated on glass coverslips that were laminin 
(20 µg/mL) coated overnight at 4ºC. 
Immunohistochemistry – Wildtype CD1 mouse brain coronal sections for 
immunohistochemistry were gifted from Dr. Dwight Bergles lab. Sections were washed in 
phosphate buffer saline (PBS) and then permeabilized with 0.3% Triton X-100 in PBS at room 
temperature for 10 min before incubated in blocking buffer containing 0.3% Triton X-100 and 5% 
normal donkey serum in PBS. Next, sections were incubated with primary antibody anti-STAC 
(stac1) antibody [EPR12805]-N-terminal diluted in blocking buffer (1:100, ab181157) overnight 
(16-18 hr) at 4ºC on a shaker and then washed with PBS for 5 min 3x. Sections were incubated 
with secondary antibody goat anti-rabbit IgG Alexa Fluor 594 (1:1000, ab150080) diluted in 
blocking solution for 2 hr at room temperature in the dark and then washed in PBS for 5 min 3x. 
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During the second wash, DAPI (1:10000, D21490) was added. Finally, sections were mounted on 
charged glass-slides with Aqua Ploy/Mount (18606, Polysciences, Inc.) and covered with a glass 
coverslip. 
aGPVMs plated on glass coverslips were first washed 3x with cold PBS and then fixed in 
3.7% paraformaldehyde (15710, Electron Microscopy Sciences) in PBS for 15 min. After washing 
3x with PBS, cells were permeabilized in cold 0.5% Triton X-100 in tris buffered saline (TBS) for 
20 min and then blocked with 10% goat serum in PBS for 1 hr at room temperature. Cells were 
incubated in primary antibodies monoclonal anti-α-actinin (sarcomeric) antibody produced in 
mouse (1:300, A7811) and stac1 (1:100) or anti-STAC2 (stac2) antibody-N-terminal (1:100, 
ab156080) in antibody diluent solution (IW-1000, IHC World) overnight at 4ºC. Next day, cells 
were rinsed 3x with 0.05% TWEEN20 (Sigma P9416) in TBS (TBS-T) for 5 min each. In the dark, 
cells were incubated with secondary antibodies, (1:1000), antibodies used: goat anti-mouse IgG1 
Alexa Fluor 488 (1:1000, A21121), goat anti-rabbit IgG Alexa Fluor 594 (1:1000), and DAPI 
(1:10000) diluted in antibody solution for 45 min at room temperature and then washed 3x with 
TBS-T for 5 min each. Stained cells were mounted with prolong gold mounting media (Invitrogen) 
on a microscope slide (Fischer Scientific). 
Transfected HEK293 were immunostained following a similar protocol as aGPVM but 
were not labelled with sarcomeric primary antibody and its respective secondary antibody.  
Whole-cell electrophysiology – Whole-cell electrophysiology was performed at room 
temperature 1-4 days after transfection with Axopatch 200A (Axon Instruments). Glass pipettes 
were made from borosilicate glass (BF150-86-10, Sutter Instruments) to be 1-3 MΩ resistance 
with a horizontal puller (P-97; Sutter Instruments Company) and fire polisher (microforge, 
Narishige, Tokyo, Japan). We low-pass filtered recordings at 2 kHz, sampled at 10 kHz, and used 
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P/8 leak subtraction with 70% series resistance and capacitance compensation. Internal solution 
contained (in mM): CsMeSO3, 114; CsCl2, 5; MgCl2, 1; MgATP, 4; HEPES, 10; BAPTA, 10; 
adjusted to 295 mOsm with CsMeSO3 and pH 7.4 with CsOH. External solution contained (in 
mM): TEA-MeSO3, 140; HEPES, 10; CaCl2, 40; adjusted to 300 mOsm with TEA-MeSO3 and pH 
7.4 with TEA-OH. For measuring charge movements, we added 0.2 mM LaCl3 and 1.0 mM CdCl2 
to the external solution. We used a holding potential of -80 mV, family of test pulses from -30 mV 
to +80 mV in 10 mV increments, and repetition interval of 20 s for all whole-cell recordings. 
Custom MATLAB (Mathworks) software was used to determine peak current, average peak 
densities, fraction of peak current remaining after 300 ms depolarization (r300), and Ca2+-CaM 
dependent inactivation (CDI, ƒ300 = r300/Ba – r300/Ca / r300/Ba) plotted with SEM.  
Peak current density-voltage curves were fit with the following equation: 
                             𝐽𝑝𝑒𝑎𝑘 = 𝐺𝑚𝑎𝑥(𝑉 − 𝑉𝑟𝑒𝑣)/(1 − 𝑒𝑥𝑝[−(𝑉 − 𝑉1/2)/𝑘𝐺])                                  (2.1) 
where Jpeak is the peak current density at test potential V, Gmax is maximal channel conductance, 
Vrev is the reversal potential, V1/2 is the half-activation voltage, and kG is the slope factor (Table 
2.2). 
Normalized gating charge-voltage curves were fit with the following equation: 
 (2.2) 
 
where Qnorm is the gating charge movement at voltage V normalized to value at + 80 mV. Gating 
charge movement is composed a double Boltzmann relation, with Qmax as saturating normalized 
gating charge, V1/2.a and V1/2.b are half-activating potentials for the two components, SFa and SFb 
are slope factors for the two components.  
norm max
1/2, a a 1/2, b b
1
1 exp( ( ) / ) 1 exp( ( ) / )
f fQ Q
V V SF V V SF
  
   
       
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 We incubated aGPVMs 24-48 hr after isolation in 5 µM ryanodine for 5-10 min before we 
collected whole-cell recordings with the same setup and Axopatch 200A or 200B (Axon 
Instruments). Internal solution was the same as used in HEK293 experiments except with the 
addition of 5 mM DTT and 5 µM ryanodine. Cells were sealed in Tyrodes solution, which 
contained (in mM): NaCl, 135; KCl, 5.4; CaCl2, 1.8; MgCl2, 0.33; NaH2PO4, 0.33; HEPES, 5; 
glucose, 5 (pH 7.4). External solutions for voltage-clamp protocol were the same as those used in 
HEK293. Welch’s T-test was used to verify statistical significance between the population data. 
For CDI recordings, we determined required sample size based on power analysis. Based on 
historical estimates of normal variation in CDI/CDF measurements, we computed the sample size 
required such that type I and type II errors are 5% to be 3.5. Thus, we obtained at least 4 
independent measurements for all electrophysiological experiments.  
Current-clamp recordings of aGPVMs were performed on the same setup and were filtered 
at 5 kHz and sampled at 25 kHz. Internal solution contained (in mM): K glutamate, 130; KCl, 9; 
NaCl, 10; MgCl2, 0.5; EGTA, 0.5, MgATP, 4; HEPES, 10; adjusted to pH 7.3 with KOH. External 
solution contained (in mM): NaCl, 135; KCl, 5.4; CaCl2, 1.8; MgCl2, 0.33; NaH2PO4, 0.33; HEPES, 
5; glucose, 5 (pH 7.4). The time from upstroke to 80% repolarization (APD80) was measured with 
custom MATLAB (Mathworks) software and used as a metric for comparing physiological output 
between peptide treated and untreated. For experiments with U-peptide, peptide was dissolved in 
ddH2O to 2 mg/mL and then diluted to 500 nM in the appropriate internal solution. 
Single-channel electrophysiology – Single-channel recordings were performed at room 
temperature using an on-cell configuration previously established in the laboratory (Tay et al., 
2012) with same setup as whole-cell electrophysiology. Glass pipettes were pulled and polished 
from ultra-thick-walled borosilicate glass (BF200-116-10, Sutter Instruments) and coated with 
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sylgard to have 5-10 MΩ resistance. Recordings were filtered at 2-5 kHz. Pipette solution 
contained (in mM): TEA-MeSO3, 140; HEPES, 10; BaCl2 40; adjusted to 300 mOsm with TEA-
MeSO3 and pH 7.4 with TEA-OH. External solution contained (in mM): K glutamate, 132; KCl, 
5; NaCl, 5; MgCl2, 3; EGTA, 2; HEPES, 10; adjusted to 300 mOsm with glucose and pH 7.4 with 
KOH. Cell-attached single-channel currents were measured during 200 ms voltage ramps between 
-80 to +70 mV (portions between -50 and 40 mV displayed and analyzed) as previously described. 
For each patch, we recorded 80-150 sweeps with a repetition interval of 12 s. Patches were 
analyzed as follows: (1) The leak for each sweep was fit and subtracted from each trace. (2) The 
unitary current relation, i(V), was fit to the open-channel current level using the following equation: 
           S S S( ) ( ) exp( ( ) /( )) / (1 exp( ( ) /( )))i V g V V V V z F R T V V z F R T                 (2.3) 
where g is the single-channel conductance (~0.2 pA/mV), z is the apparent valence of permeation 
(~2.1), F is Faraday’s constant, R is the gas constant, and T is the temperature in degrees Kelvin 
(assumed room temperature). These parameters were held constant for all patches, except for slight 
variations in the voltage-shift parameter Vs ~35 mV, as detailed below. (3) All leak-subtracted 
traces for each patch were averaged (and divided by the number of channels in the patch) to yield 
an I–V relation for that patch. Since slight variability in VS was observed among patches, we 
calculated an average VS for each construct, VS,AVE. The data from each patch was then shifted 
slightly in voltage by an amount V = VS,AVE – VS, with V typically about ± 5 mV. This maneuver 
allowed all patches for a given construct to share a common open-channel GHK relation. Thus 
shifted, the I–V relations obtained from different patches for each condition/construct were then 
averaged together. (4) PO at each voltage was determined by dividing the average I (determined in 
step 3 above) into the open-channel GHK relation. Channel number was determined by the 
maximal number of overlapping opening events upon application of the channel agonist Bay 
15 
 
K8644 (5 M) at the end of each recording. For modal analysis, a dashed line discriminator was 
chosen to be average single-trial PO = 0.075 such that traces with average single-trial PO > 0.075 
was categorized as high PO while the remaining ones were considered low PO.  
Quantitative calcium photo-uncaging – All Ca2+-uncaging experiments were conducted 
on a Nikon TE2000 inverted microscope with a Plan Fluor Apo 40× oil objective as previously 
described (Ben-Johny et al., 2014). Briefly, a classic Cairn UV flash photolysis system was used 
for Ca2+-uncaging with brief UV pulses of ~1.5 ms in duration powered by a capacitor bank of up 
to 4000 F charged to 200-290V. For concurrent Ca2+ imaging, Fluo4FF and Alexa568 dyes were 
dialyzed via patch pipet and imaged using Argon laser excitation (514 nm). Background 
fluorescence for each cell was measured prior to pipet dialysis of dyes and subtracted subsequently. 
A field-stop aperture was used to isolate fluorescence from individual cells. Dual-color 
fluorescence emission was attained using a 545DCLP dichroic mirror, paired with a 545/40BP 
filter for detecting Fluo4FF, and a 580LP filter for detecting Alexa568. Typically, uncaging 
experiments were conducted after ~2 minutes of dialysis of internal solution. Welch’s T-test was 
used to verify statistical significance between the population data. 
FRET-two hybrid assay – Three-cube FRET fluorescence of transfected HEK293 cells 
were measured on an inverted fluorescence microscope in 2 mM Ca2+ Tyrodes under resting Ca2+ 
intracellular concentrations and 10 mM Ca2+ Tyrodes incubated with 4 µM ionomycin (Sigma 
Aldrich) under Ca2+/CaM conditions. Different concentrations and ratios of DNA were transfected 
to achieve a range of donor molecule (Dfree) concentrations. FRET efficiency (EA) for each 
individual cell was calculated (Erickson et al., 2001) and effective dissociation constants (Kd,EFF) 
was computed by fitting the binding curve: EA = [Dfree]/(Kd,EFF + [Dfree]) · EA,max iteratively. For 
stac3 NAM constructs where plateaus of FRET binding curves were not clearly defined by data, 
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we assumed stac3 adopts the same conformation and possess the same EA,max (Ben Johny et al., 
2013). 
Bungarotoxin-labelling assay – First, we washed transfected cells twice with DPBS (with 
Mg2+ and Ca2+) (MediaTech). Then, we blocked unspecific binding sites with 3% BSA/DMEM 
for half an hour at room temperature. We incubated cells with 1 µM α-bungarotoxin-biotin 
(Invitrogen) in 3% BSA/DMEM for 1 h at room temperature in the dark. On ice and in the dark, 
cells were washed twice with DPBS, incubated 3 times for 5 min. with DPBS, and incubated for 
1 h with 10 nM Qdot655 for flow cytometry or Qdot605 for confocal imaging (Invitrogen) in 3% 
BSA/DMEM. Finally, cells were washed with DPBS and imaged on the confocal microscope in 2 
mM Ca2+ Tyrodes or harvested with trypsin, washed with PBS (without Mg2+ and Ca2+), and 
resuspended for flow cytometry. 
The total GFP fluorescence is proportional to the number of channels in a cell, 
 G tot G 0S N I    (2.4) 
where αG corresponds to the brightness of single GFP given the imaging setup and I0 is the intensity 
of the excitation lamp. Similarly, the number of channels at the plasma membrane is given by,  
 R surface R 0(4 )S N I       (2.5) 
where αR corresponds to the brightness of single QD molecule when assessed through our imaging 
setup and I0 is the intensity of the excitation lamp, and 4 corresponds to the stoichiometry for 
biotin-streptavidin interaction. The factor ε is the efficiency of QD labeling. The ratio of the two 
equations yields  
 (2.6) 
and is proportional to the fraction of surface-membrane channels.  
surfaceR R R
mem
G tot G G
4 4NS f
S N
   

 
   
   
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Confocal optical imaging – We captured exemplar images of bungarotoxin-labelled HEK 
cells with the Olympus Fluoview FV300 confocal laser scanning microscope and Fluoview 
software (Olympus). Using the Olympus PlanApo 403 or 603 oil objective (NA 1.40, 
PLAPO60XO3; Olympus), GFP was excited with an Argon Laser (488 nm), and Qdot-605 
streptavidin conjugate (Invitrogen) was excited with Helium Neon (HeNe) Green Laser. Olympus 
optical filters used include 442/515 nm excitation splitter (FV-FCV), 570 nm emission splitter 
(FV-570CH), BA510 IF and BA530RIF for GFP emission channel, and 605BP filter for Qdot 
channel. Images were converted and merged on ImageJ. 
Images of immunostained tissue slices and cells were captured with an LSM780 (Carl Zeiss, 
Oberkochen, Germany) confocal microscope. Similar settings were used for the LSM780 setup. 
Flow cytometry – Fluorescence of harvested cells were measured with an Attune acoustic 
focusing flow cytometer (Life Technologies) in the “high-sensitivity” mode with a flow rate of 
100 µL/min. We used the blue (488 nm) laser to excite GFP and Qdot to collect green and red 
fluorescence respectively. Green fluorescence was measured through the 574/26 optical filter. 
Likewise, red fluorescence was measured through the 640LP optical filter. Flow cytometer was 
calibrated and maintained as previously published (Lee et al., 2016). Control experiments prepared 
include un-transfected cells, GFP only cells, cells transfected with CaV1.1 and stac3 as a negative 
control, and cells with CaV1.1BBS and stac3 as a positive control. Data was exported as FCS files 
and analyzed with custom MATLAB (Mathworks) software. 
Data processing statistical analysis – Raw data was gated by forward and side scatter 
signals to filter for single and healthy cells and green signals above 1.5×105 units were excluded 
because of non-linearities in flow cytometer measurements (Lee et al., 2016). Red signals above 
2×105 units were excluded because of PMT saturation and accounted for <1% of total collected 
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points. To correct for the true green (SG) and red (SR) signals, we averaged red signal (ŜR,blank) and 
green signal (ŜG,blank) of blank cells. We also calculated the slope for GFP bleed-through into the 
red channel (fRED,GFP) due to the broadness of the GFP emission spectrum to be ~2.65%, yielding 
two equations: SG = ŜG - ŜG,blank and ŜR = SR - ŜR,blank - fRED,GFP · SG , where ŜG is the raw green 
signal and SRED is the red signal. Welch’s t-test was used to statistically compare two trafficking 
conditions and p-value reports the probability for the null hypothesis that the respective ϕmax for 
conditions compared are equal. To ensure robustness, we also used a rank-sum test. In all cases, 
the p-values for rank-sum test was similar to that with Welch’s t-test. Number of independent trials 
and total number of cells analyzed are listed in Table 2.3. 
Langmuir analysis of CaV1.1 surface membrane trafficking – The lifecycle of an ion 
channel is complex involving the production of new channels, transport between multiple sub-
cellular organelles, quality control, and protein degradation. While these events occur in distinct 
organelles, here we consider a simplified model to quantify changes in the proportion of surface-
membrane trafficked channels elicited by the binding of a regulatory protein such as stac3 in 
single cells. Channels can thus be envisioned to traffic between the two compartments, the 
surface membrane and an aggregate internal compartment that includes organelles such as the 






More specifically, channels are assumed to be produced within the internal compartment at a rate 
of kc and degraded at a rate kd. As fully folded channels feature binding sites accessible to cytosolic 
regulatory proteins, we assume that they may interact with the channel at both the plasmalemmal 
and internal compartments. Moreover, the transport of proteins between the two compartments is 
typically slow by comparison to binding and unbinding of regulatory proteins. Consequently, we 
assume that channel complexes are at ‘rapid equilibrium’ within each compartment.  
The rate of forward trafficking and internalization for channel complexes may be different 
depending upon what regulatory proteins are bound. For simplicity, here we probe how the binding 
of a single regulatory molecule (L1) alters channel surface-membrane trafficking. Thus, in both the 
internal and plasma-membrane compartments, the binding of regulatory agent interconverts 
channels between the unbound and bound conformations indexed by 0 and 1 respectively. For 
channel complexes without the pertinent regulatory protein, the rate of forward trafficking is 𝑗0+ 
while the rate of reverse trafficking is 𝑗0−. For channels bound to the regulatory molecule, the 
forward trafficking rate is 𝑗1+ and reverse trafficking rate is 𝑗1−. The differences in forward and 
reverse trafficking for the two classes of complexes ultimately lead to changes in the proportion 
of surface-membrane channels. Given ‘rapid-equilibrium,’ the dynamics of number of channels in 
internal (Ni) and plasma-membrane (Npm) compartments are given by the following differential 
equations,  
 pm eff i eff pm
dN
j N j N
dt
      (2.7) 
 i c eff pm eff i d
dN k j N j N k
dt
        (2.8) 
where effj
 and effj
 are the effective rates of forward and reverse trafficking respectively. As the 
total number of channels NT = Ni + Npm, Eq. 2.7 can be simplified further as,  
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 pm eff T pm eff pm eff T eff eff pm( ) ( )
dN
j N N j N j N j j N
dt
               (2.9) 
Moreover, the dynamics of the total number of channels is given as the sum of Eqs. 2.7 and 2.8, 
 T c d
dN k k
dt
   (2.10) 
If kc and kd are constant with respect to time and NT, then NT will increase linearly with time post-
transient transfection (t), i.e. NT = (kc - kd) · t. That said, kc and kd are variable depending upon 
cellular regulatory factors and cell status, indicating that NT may be non-linear with respect to time 
post-transfection. Nonetheless, if both kc and kd are slow in comparison to the rates of forward 
trafficking and reverse trafficking, then the pseudo-steady-state value for the number of plasma 




















Given rapid-equilibrium, the effective rate of forward trafficking is,  
 eff 0,i 0 1,i 1j P j P j
       (2.13) 
P0,ic and P1,ic corresponds to the probabilities that a channel in the internal compartment is either 
unbound or bound to regulatory ligand. Of note, these probabilities depend upon the concentration 
L1 of the regulatory protein in the intracellular compartment. 
 1 1,i0,i 1,i
1 1,i 1 1,i




K L K L

 
   
 (2.14) 
Similarly, the net rate of internal trafficking is,   
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 eff 0,pm 0 1,pm 1j P j P j
       (2.15) 
P0,pm and P1,pm corresponds to the probability that a channel in the plasma membrane compartment 
is either unbound or bound to the trafficking modulator. Akin to Eq. 2.14, these probabilities follow 
a Langmuir relation with the concentration of the trafficking modulator in the plasma membrane 
compartment (L1,pm),  
 1 1,pm0,pm 1,pm
1 1,pm 1 1,pm




K L K L

 
   
 (2.16) 
In the specific case of Stac3 and CaM that bind to channel cytosolic loops, L1,pm = L1,i = L1 the 
cytosolic concentration of the trafficking modulator of interest. Thus, P0,pm = P0,i and P1,pm = P1,i. 
Consequently,  
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  
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    
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j j j j j j L K
 
     
 
    
    
 (2.17) 
 
Recall that the surface-membrane trafficking ratio φ is given by,  
 0 0R R R R 1 1mem
G 0 0 1 1 0 0 1 1
4 4 4
1/G G G
j jS j Kf
S j j j j j j L K




     
      
         
    
 (2.18) 
where the constants αR, αG, and ε are as defined in the main text. Thus, if mutations were to 
specifically perturb the binding of the trafficking modulator L1 to its effector interface on the 
channel, then then net fraction of surface-membrane channels will follow a Langmuir relation with 
the association constant (Ka) for the mutant. A specific relationship for stac3 is described as follows,  
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Table 2.1. List of primers and sequences. 







CaV1.3, α2δ, β2a 1239.2.0±237.7 82.2±1.1 0.8±1.4 7.3±0.5 
CaV1.1 (1 day), α2δ, β2a N.D. 
CaV1.1-CaV1.3 CT, α2δ, β2a 460.0±82.0 96.7±2.2 42.5±1.9 10.8±0.5 
CaV1.1, α2δ, β2a, CaM 763.3±205.4 86.7±2.1 39.7±1.6 10.8±0.4 
CaV1.1, α2δ, β2a-CaM 624.3±113.9 88.8±2.0 37.3±2.1 10.2±0.3 
CaV1.1, α2δ, β2a, stac3 978.0±177.7 81.7±3.3 29.9±1.8 10.1±0.3 
CaV1.1-G-CaM, α2δ, β2a 266.7±92.8 101.7±6.0 40.0±5.0 11.8±0.2 
CaV1.1(BBS), α2δ, β2a-CaM 790.0±3011.2 85.0±6.0 36.8±1.4 10.1±0.3 
CaV1.1 (4 days), α2δ, β2a 189.2±23.1 73.8±5.2 36.3±2.5 9.5±0.3 
CaV1.1, α2δ, β2a, stac3W284S + 0.5µM 
verapamil 1708.3±447.3 81.5±5.2 33.0±2.1 9.7±0.8 
Table 2.2. Current-voltage parameters for whole-cell electrophysiology experiments and fit 




Condition # trials # cells 
CaV1.1, no β 2 18008 
CaV1.1, no β, stac3 2 19925 
CaV1.1ΔCT, β1a 3 629 
CaV1.1ΔCT, β2a-CaMWT 3 304 
CaV1.1ΔCT, β1a, stac3 3 548 
CaV1.1, β2a-CaMWT 4 39972 
CaV1.1, β2a-CaMWT, CaMWT 2 22459 
CaV1.1, β2a-CaMWT, stac3 3 20055 
CaV1.1, β2a, stac3 5 64747 
CaV1.1, β1a, stac3, CaMWT 5 71312 
CaV1.1, β1a, stac3 L[111]Δ 5 81648 
CaV1.1, β1a, stac3 L[111]Δ, CaMWT 3 33545 
CaV1.1, β1a, stac3 K[288]* 5 58437 
CaV1.1, β1a, stac3 K[288]*, CaMWT 4 11185 
CaV1.1, β1a, stac3W[284]S, CaMWT 3 41228 
CaV1.1, β1a, stac3 W[284]S 9 107065 
+no drug (24hr) + no wash (24 h) 3 20593 
+2 µM ranolazine (24 h) 2 34094 
+6 µM ranolazine (24 h) 2 32330 
+3 µM mexiletine (24 h) 2 29616 
+10 µM mexiletine (24 h) 2 22357 
+0.15 µM nifedipine (24 h) 2 38387 
+0.3 µM nifedipine (24 h) 2 33858 
+0.25 µM diltiazem (24 h) 4 59120 
+0.5 µM diltiazem (24 h) 3 45466 
+wash day 1 (24 h) 3 18956 
+0.5 µM verapamil (24 h) 4 66809 
+1.0 µM verapamil (24 h) 3 36545 
+1.0 µM verapamil (24 h) + wash (24 h) 3 18405 
+1.0 µM verapamil (24 h) + no wash (24 h) 3 23608 
CaV1.1, β1a 4 23021 
+1.0 µM verapamil (24 h) 2 18114 
CaV1.1, β2a 5 36106 
+48 h 2 7694 
+72 h 2 6227 
+96 h 2 6073 
CaV1.1, β2a-CaM1234 4 35731 
CaV1.1, β2a-RyR1(P2) 2 12474 
CaV1.1, β1a, stac3(C1) 3 9946 
CaV1.2, β2a 4 23476 
CaV1.2, β2a, stac3 5 12018 
CaV1.1, β1a, CaMWT 6 57821 
+1.0 µM verapamil (24 h) 3 50551 
+0.5 µM diltiazem (24 h) 3 49569 
CaV1.1, β1a, stac3 38 306786 
+1.0 µM verapamil (24 h) 1 18210 
+0.5 µM diltiazem (24 h) 1 19769 
 




     CHAPTER 3      
Duplex signaling by CaM and stac3 enhances CaV1.1 function and unveils 
pharmacological insights for congenital myopathy 
   
Central to excitation-contraction (EC) coupling in skeletal muscle, CaV1.1 is an L-type 
voltage-gated calcium (Ca2+) channel that senses transmembrane depolarization to initiate Ca2+ 
release from the sarcoplasmic reticulum (SR) via the ryanodine receptor (RyR1) (Bannister and 
Beam, 2013; Schneider and Chandler, 1973). While its cardiac counterpart, CaV1.2, communicates 
with RyR2 via freely diffusing Ca2+ ions, CaV1.1 is conformationally coupled to RyR1 obviating 
the intermediary second messenger (Armstrong et al., 1972; Rios et al., 1992; Tanabe et al., 1990a). 
This intimate physical linkage warrants a precise geometric arrangement of the two partners in the 
skeletal myotube – four CaV1.1, termed tetrads, are disposed in ordered arrays that parallel RyR1 
arrays at the surface-membrane/SR (peripheral-couplings) or tubular-membrane/SR (triad) 
interfaces (Franzini-Armstrong and Jorgensen, 1994; Lamb, 2000).  
Fitting with this physiology, a cohort of auxiliary subunits such as β1A (Schredelseker et 
al., 2009), α2δ (Obermair et al., 2005), γ1 (Freise et al., 2000) and various SR proteins including 
RyR1 (Avila and Dirksen, 2000; Bannister et al., 2016; Nakai et al., 1996), junctional protein 45 
(JP45) (Anderson et al., 2006), and junctophilin (Golini et al., 2011) tune CaV1.1 function. To 
identify essential signaling partners, a ‘top-down’ approach using primary cultures of skeletal 
myotubes obtained from gene knock-out (KO) models (Obermair et al., 2008) and cell-lines 
derived from dysgenic and normal myotubes have been insightful (Powell et al., 1996). However, 
such analyses have often reveal overlapping functions, whereby loss of a single protein 
dramatically alters CaV1.1 localization and/or gating to ultimately disrupt EC coupling. These 
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effects may either be direct or indirect depending on other proteins present in the complex. Thus, 
quantifying the role of a given modulator on CaV1.1 and the underlying regulatory mechanism is 
challenging. Intriguingly, recent studies have revealed that both calmodulin (CaM) (Ohrtman et 
al., 2008; Stroffekova, 2008) and stac3 regulate CaV1.1 though underlying mechanisms remain to 
be fully elucidated (Horstick et al., 2013; Linsley et al., 2017a; Polster et al., 2015).  
To resolve these complex channel regulatory mechanisms, a ‘bottom-up’ approach 
whereby the effects of individual signaling molecules on CaV1.1 gating and trafficking are probed 
in a simplified system without an elaborate SR or t-tubules would be greatly beneficial (Dascal et 
al., 1992; Perni et al., 2017; Polster et al., 2015). However, functional analysis of CaV1.1 and its 
modulation by various signaling molecules in non-muscle cell systems remain challenging (Dascal 
et al., 1992; Johnson et al., 1997; Perez-Reyes et al., 1989; Polster et al., 2015). While homologous 
CaV1.2, CaV1.3 and CaV1.4 all exhibit reliable surface-membrane trafficking in heterologous 
systems in the presence of α2δ and β auxiliary subunits (Catterall, 2000; McRory et al., 2004; 
Mikami et al., 1989; Xu and Lipscombe, 2001), CaV1.1 is thought to be retained in internal 
organelles (Linsley et al., 2017b; Polster et al., 2015). Countering this classical purview, however, 
a recent functional study demonstrated that the cytosolic adaptor protein stac3 with the α2δ/β-
subunits, enabled CaV1.1 expression in human derived tsA201 cells (Polster et al., 2015). Further 
analysis suggested that additional factors including the transmembrane γ1 subunit may also permit 
CaV1.1 expression in tsA201 cells (Polster et al., 2016). The contrasting molecular requirements 
that permit CaV1.1 expression in heterologous systems obfuscate general principles that underlie 
channel trafficking and precludes systematic analysis of channel gating. 
In this chapter, we demonstrate that CaV1.1, in fact, traffics to the plasma membrane of 
recombinant cell systems in the presence of auxiliary α2δ and β-subunits alone. However, this 
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baseline expression is lower than that for homologous L-type channels. Moreover, 
electrophysiological analysis reveals tiny ionic currents suggesting that CaV1.1 has a low baseline 
PO. Both CaM and stac3 enhance both surface-membrane trafficking and baseline PO of CaV1.1. 
Moreover, we demonstrate that stac3 binds to the CT of CaV1.1, and stac3 mutations associated 
with congenital myopathy weaken this interaction resulting in reduced channel surface-membrane 
trafficking. Delivery of CaM to the channel complex can strikingly reverse this trafficking defect. 
Interestingly, long-term application of small-molecule CaV modulators diltiazem and verapamil 
yields a partial rescue of channel trafficking.  
RESULTS 
The carboxy-terminus is a structural determinant for functional expression of CaV1.1 – 
In comparison to other L-type Ca channels, CaV1.1 expresses poorly in heterologous cell systems 
(Perez-Reyes et al., 1989; Polster et al., 2015). Figure 3.1A shows exemplar inward Ca2+ current 
elicited in response to a voltage-step depolarization from a HEK293 cell transiently expressing 
CaV1.3 pore-forming α1 subunit with auxiliary β2A and α2δ subunits. Population data of average 
peak current densities elicited in response to a family of step-depolarizations further illustrate 
robust expression of CaV1.3 in HEK293 cells (Figure 3.1A). In contrast, when CaV1.1 α1 subunit 
is coexpressed with both β2A and α2δ auxiliary subunits, we observe minimal ionic currents (Figure 
3.1B). Given the functional difference between CaV1.1 and CaV1.3 despite their overall structural 
similarity, we undertook a chimeric approach by exchanging the carboxy-terminus (CT) of CaV1.1 
α1 subunit with that of CaV1.3 to identify motifs that enable channel function. Electrophysiological 
analysis revealed robust currents for the chimeric channels (Figure 3.1C) suggesting that the CT 
is a key determinant for functional expression.  
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One possibility is that CaV channel function may be enabled by modulatory partners that 
interact with the CT interface. For nearly all CaV1/2 channels, CaM is one such well-established 
partner known to modulate channel function (Lee et al., 2000; Liang et al., 2003; Peterson et al., 
1999; Pitt et al., 2001; Qin et al., 1999; Singh et al., 2006; Yang et al., 2006; Zuhlke et al., 1999). 
Consequently, we explored differences in CaM binding to CaV1.3 versus CaV1.1 using FRET 
(Forster Resonance Energy Transfer) two-hybrid binding assay (Erickson et al., 2001) in live cells. 
We co-expressed cerulean-tagged CaM (Cer-CaMWT) with venus-tagged CaV1.3 CT including the 
dual vestigial EF hands, the preIQ and IQ domains (Ven-CaV1.3 CI) and measured FRET 
efficiency (EA) between the donor-acceptor pair (Figure 3.1G). As cells transfected with these 
constructs variably express the fluorophore-tagged partners, EA measured from single cells follow 
a Langmuir binding relation with the free concentration of the donor. The CaV1.3 CI exhibited 
strong binding to Cer-CaMWT under both basal and elevated Ca2+-conditions (Figure 3.1H and 
Figure 3.1G respectively) consistent with prior studies (Ben Johny et al., 2013). In contrast, FRET 
two-hybrid analysis of Venus-tagged CaV1.1 CI (Ven-CaV1.1 CI) and Cer-CaMWT showed weaker 
binding under both basal and elevated Ca2+-conditions (Figure 3.1J and Figure 3.1I respectively). 
Thus, the lack of functional expression of CaV1.1 versus CaV1.3 in heterologous systems may be 
the consequence of weak or absent CaM binding. If so, then reinstatement of CaM to CaV1.1 should 
rescue channel function. Consequently, we overexpressed CaM with CaV1.1 and its auxiliary 
subunits and demonstrated partial rescue of functional Ca2+ currents (Figure 3.1D). Furthermore, 
to ensure robust CaM binding, we localized CaM to the CaV1.1 complex by fusion to the β2A 
auxiliary subunit. This manipulation also enabled functional expression of CaV1.1 in HEK293 cells 




Next, we explored whether other modulatory partners also enable channel function via 
binding to the CaV1.1 CT. Recent studies have reported that CaV1.1 currents can be re-established 
in HEK293 cell systems by co-expression of stac3 (Polster et al., 2015), an adaptor protein 
essential for skeletal muscle function. While stac is structurally unrelated to CaM, we considered 
whether stac might mimic CaM action in the context of skeletal muscle, and rescue channel 
function by binding to channel CT. Exemplar current trace and population data (Figure 3.1F) 
confirm robust CaV1.1 functional expression in HEK293 cells following co-expression of stac3. 
FRET two-hybrid analysis of Cer-tagged stac3 with Ven-CaV1.1 CI revealed strong binding 
(Figure 3.1K) with Kd,EFF ~ 12000 Dfree units ~ 400 nM. Thus, the occupancy of CaV1.1 CT appears 
to be closely linked to proper channel function and an emerging repertoire of CT-binding proteins 
may modify CaV function in heterologous and native cells via redundant mechanisms (Flynn and 
Altier, 2013; Hall et al., 2013; Marshall et al., 2011; Park et al., 2010; Wang et al., 2010).  
CaM and stac enhance CaV1.1 surface membrane trafficking – As both CaM and stac 
partially rescue CaV1.1 function, we sought to discern underlying molecular mechanisms. The 
functional expression of ion channels may be enhanced from changes in three vital parameters: 1) 
the number of channels at the surface membrane dictated by protein trafficking, 2) ion permeation, 
and 3) channel gating.  
To quantify the relative fraction of channels at the cell surface membrane, we used a dual 
labeling approach (Yang et al., 2010) whereby the α1 subunit is tagged with both a GFP on the 
cytoplasmic amino-terminus and an external epitope composed of a 13 amino-acid α-
bungarotoxin-binding site (BBS) inserted into the extracellular loop (Figure 3.2B, CaV1.1BBS). To 
label surface membrane channels, we incubate cells with cell-impermeable biotin-conjugated α-
bungarotoxin and visualize using streptavidin covalently attached to a red quantum dot (QD) while 
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the total expression of CaV1.1 in a cell is determined by monitoring the GFP fluorescence (Sekine-
Aizawa and Huganir, 2004). The high affinity and specificity of bungarotoxin for the BBS site 
facilitates reliable detection of surface-membrane CaV1.1 with minimal background fluorescence 
(Sekine-Aizawa and Huganir, 2004). We first verified the functionality of CaV1.1BBS by co-
transfecting β2a-CaMWT into HEK cells. The resultant Ca2+ currents exhibited comparable 
properties as the unmodified CaV1.1 (Figure 3.2A). We probed baseline plasmalemmal expression 
for CaV1.1BBS in the presence of β2A and α2δ subunits using confocal imaging (Figure 3.2B). The 
left subpanel shows the transmitted light image of an exemplar cell, the middle subpanels show 
green (SG) and red (SR) fluorescence images indicating GFP from total channels and QD emissions 
from plasmalemmal channels respectively. The far-right merged image showcases the difference 
in intracellular and extracellular labeling of CaV1.1BBS. While strong GFP fluorescence is evident, 
external QD labeling is sparse indicating poor surface-membrane expression of CaV1.1 (Figure 
3.2B). That said, we did observe some surface-membrane labeling in a few cells suggesting that 
CaV1.1 with just α2δ and β subunits might be sufficient for surface-membrane trafficking, albeit 
with a poor efficacy. Analysis of external epitope labeling from a multitude of individual cells 
would help resolve such ambiguities.     
Accordingly, we used flow cytometric analysis to quantify surface-membrane trafficking 
at a population level by determining the total GFP (SG) and QD (SR) fluorescence from individual 
cells. For a given cell, the ratio of red to green fluorescence (ϕ = SR/SG) is proportional to the 
fraction of surface-membrane channels (fmem) and serves as a quantifiable metric for trafficking 
efficacy (as described in Chapter 2),   
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The factors αR and αG are brightness of single QD and GFP fluorophores respectively and ε is the 
efficiency of labeling. Given this framework, we plotted SR versus SG obtained from individual 
cells expressing CaV1.1BBS with β2A and α2δ subunits after one day of transfection (Figure 3.2C). 
Consistent with confocal imaging data, flow-cytometric analysis showed a mixed population of 
cells – a small fraction exhibits minimal surface-membrane labeling (SR = 0), while another 
demonstrates reliable QD labeling (SR > 0). Binned data reveal a saturating relationship for SR as 
SG increases, with a maximal value of ~ 1923 ± 51 (fluorescence units). We estimated the 
saturating surface-membrane trafficking limit (ϕmax) as the mean ratio ϕ for individual cells 
exhibiting high GFP fluorescence (i.e. 5.4×104 ≤SG ≤1.4×105) to be 0.0225 ± 0.0006. Here, we 
exclude values above 1.4×105 GFP fluorescence units because of previously identified non-
linearities in fluorescence measurements from our flow cytometer above this value (Lee et al., 
2016). In comparison, the ϕmax for CaV1.2BBS is approximately 0.0276 ± 0.0004 (Figure 3.2J). Of 
note, culturing transfected HEK293 cells for multiple days at 30⁰C, to reduce channel endocytosis, 
further enhances CaV1.1 surface-membrane trafficking (Figure 3.2I). This surprising finding 
furnishes a convenient strategy to study baseline properties of CaV1.1 in the absence of various 
regulatory proteins and sets the stage for mechanistic studies that assess effects on channel gating.  
With surface-membrane expression of CaV1.1 confirmed, we next sought to identify core-
requirements for channel plasmalemmal trafficking. For other L-type channels, the auxiliary β 
subunits are necessary for efficient surface-membrane trafficking (Buraei and Yang, 2010; 
Dolphin, 2003; Fang and Colecraft, 2011; Perez-Reyes et al., 1992). Indeed, CaV1.1BBS exhibits 
no QD labeling in the absence of β subunits (Figure 3.2J), suggesting that the β subunit is 
obligatory for plasma-membrane expression echoing findings in skeletal myotubes based on KO 
mouse models (Schredelseker et al., 2005). Consequently, we explored CaV1.1 plasmalemmal 
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trafficking in the presence of β1A subunits that are endogenous to skeletal myotube. Much as with 
β2A co-expression, confocal imaging (Figure 3.2H) and population analysis (Figure 3.2I) revealed 
weak but detectible QD labeling of CaV1.1BBS in the presence of β1A subunits.  
With baseline requirements for plasmalemmal expression of CaV1.1 firmly established, we 
probed the effect of CaM and stac3 on overall channel trafficking. When CaM is delivered locally 
to CaV1.1BBS via β2A-CaM, QD labeling is markedly enhanced hinting at improved plasmalemmal 
localization (Figure 3.2D). Flow cytometric analysis of CaV1.1 co-expressed with β2A-CaM 
revealed an overall enhancement in the QD labeling in comparison to levels with the β2A subunit 
alone (p < 1E-5) (Figure 3.2E; Figure 3.2J) or with β2A fused to a sham payload, the P2 domain of 
RyR1 (p < 1E-5) (Figure 3.2J). Interestingly, this increase in surface membrane expression with 
CaM seemed largely Ca2+-dependent. Co-expression of a mutant CaM (β2A-CaM1234), which 
possesses low Ca2+ binding due to alanine substitution of Ca2+-coordinating residues, with 
CaV1.1BBS only marginally enhanced QD labeling (p = 0.048) in comparison to coexpression with 
β2A alone (Figure 3.2J). Likewise, the surface membrane expression of CaV1.1 bound to the 
skeletal muscle β1A subunit is also enhanced significantly with co-expression of CaM as a separate 
molecule (p < 1E-5) (Figure 3.2J). We next explored whether stac3 also enhances the surface-
membrane trafficking of CaV1.1. Confocal imaging (Figure 3.2F) and flow cytometric analysis 
(Figure 3.2G) revealed a substantial enhancement in QD labeling for CaV1.1BBS with stac3 in the 
presence of both β2A (p < 1E-5) and β1A (p < 1E-5) subunits (Figure 3.2J). Moreover, co-expression 
of the C1 domain of stac3 alone also increased surface-membrane trafficking though partially (p 
< 1E-5) (Figure 3.2J), fitting with prior analyses showing that this domain is critical for channel 
localization at the skeletal muscle triad (Campiglio and Flucher, 2017). Even so, in the absence of 
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a β-subunit, CaV1.1BBS exhibited minimal surface-membrane expression even with co-expression 
of stac3 (Figure 3.2J).  
 As stac3 and CaM both interact with the CT, we sought to directly probe whether this 
binding is functionally critical for CaV1.1 trafficking. Accordingly, we reasoned that the deletion 
of the CT, CaV1.1(ΔCT)BBS, would abrogate stac3- and CaM-mediated enhancement in CaV1.1 
trafficking. Remarkably, coexpression of CaV1.1(ΔCT)BBS with β1A and α2δ shows significant 
enhancement in trafficking in comparison to the wildtype channel (p < 1E-5) (Figure 3.2J). 
However, co-expression of either β2A-CaM (p = 0.4) or stac3 (p = 0.11) does not further enhance 
surface-membrane trafficking of CaV1.1 (Figure 3.2J). Thus, both CaM and stac3 can individually 
enhance the surface-membrane expression of CaV1.1 via interaction with the CT; however, this 
enhancement appears to be conditional on the presence of a bound β subunit. 
Distinct binding sites on the CT allow CaM and stac3 to act independently – Given that 
both CaM and stac3 bind to the channel carboxy-tail to enhance surface-membrane expression, we 
examined whether these agents act independently or through a shared endpoint. Consequently, to 
further delineate the CT binding interface for stac3 and CaM, we parsed the CT into three distinct 
segments: dual vestigial EF hands, pre-IQ, and IQ domains. Using FRET 2-hybrid assay, we 
probed binding between Venus-tagged channel segments and Cerulean-tagged CaM or stac3. 
Ca2+/CaM exhibits a markedly higher affinity to the pre-IQ and IQ domains in comparison to the 
dual vestigial EF hand segments (Figure 3.3A-B). By contrast, stac3 preferentially binds to the 
dual vestigial EF hand segments in comparison to the preIQ and IQ domains (Figure 3.3C-D). 
These findings demonstrate that stac3 and CaM prefer distinct CT interfaces.  
Thus, we probed surface-membrane labeling of CaV1.1BBS in the presence of both β2A-CaM 
and stac3. If the two agents act through a shared endpoint, then their combination will not further 
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increase trafficking. However, flow cytometric analysis revealed that the two agents 
combinatorically enhance the trafficking of CaV1.1BBS nearly 6-fold suggesting that they act 
independently through distinct sites on the CT (p < 1E-5) (Figure 3.3E-G). Analogously, 
CaV1.1BBS expressed with β1A, CaM, and stac3 yields an 8-fold increase in trafficking. By contrast, 
co-expression of freely-diffusing CaM with CaV1.1BBS and β2A-CaM did not further enhance 
trafficking (p = 0.13) (Figure 3.3G) suggesting that the additive effect here did not result from 
incomplete saturation of channel CT by CaM. Together, these findings suggest that CaV1.1 
plasmalemmal trafficking is enriched by a duplex signaling mechanism. 
CaM and stac3 enhance the open probability of CaV1.1 – With the role of CaM and stac3 
on CaV1.1 trafficking established, we probed their effects on channel gating. However, as the 
activation of CaV1.1 is right-shifted to near its reversal potential (Table 2.2), detecting single-
channel openings reliably in an ‘on cell’ configuration is challenging as the unitary currents at 
these voltages are small. Thus, to estimate changes in the maximal open probability, we analyzed 
macroscopic Itail and overall gating charge movement. More specifically, the peak Itail is linearly 
proportional to both the steady-state PO of the channel at the activating pre-pulse potential and the 
number of surface-membrane channels. However, the total gating charge moved at the reversal 
potential (qrev) is proportional to the number of surface-membrane channels. Gating charges can 
be isolated by blocking ion currents with heavy metals Cd2+/La3+. Thus, the ratio, Itail / qrev, is 
linearly proportional to PO and serves as a convenient proxy to estimate changes in PO,max under 
various conditions.  
While our initial functional studies failed to detect appreciable CaV1.1 currents with 
auxiliary β2A and α2δ subunits co-expressed (Figure 3.1B), these experiments were conducted one 
day following transient transfection. Our trafficking studies instead showed that CaV1.1 surface-
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membrane expression with the same subunits is substantially enhanced (p < 1E-5) several days 
following transient transfection (Figure 3.2I). As such, we conducted whole-cell patch clamp 
experiments of CaV1.1 with auxiliary β2A and α2δ subunits four days following transfection. 
Scrutiny of current recordings revealed substantial gating currents in response to a 100-ms 
activating pulse to +80 mV indicating the presence of surface membrane channels (Figure 3.4A; 
labeled Q). The duration of the activating pulse was chosen to accommodate the ultra-slow 
activation of CaV1.1, but the tail currents (Itail) elicited at 0 mV following this activation pulse was 
comparatively small. Moreover, blockade of ionic currents revealed both ‘ON’ gating current, in 
response to a depolarizing pulse, and ‘OFF’ gating current during repolarization (Figure 3.4B). 
Computing Itail / qrev demonstrated low saturating values consistent with a diminished baseline 
PO,max of CaV1.1 channels (Figure 3.4C). Moreover, normalized ‘ON’ and ‘OFF’ gating charges 
plotted as a function of voltage overlays upon each other demonstrating that QON and QOFF were 
similar in magnitude and voltage-dependence (Figure 3.4D; Figure 3.4S). In contrast, with CaM 
or β2A-CaM co-expressed, CaV1.1 produce markedly enhanced Itail (Figure 3.4E and Figure 3.4I) 
with similar gating currents (Figure 3.4F and Figure 3.4J). Further analysis shows that the 
saturating value of Itail / qrev is ~ 5-fold enhanced in the presence of CaM (Figure 3.4G, p = 0.006) 
or β2A-CaM (Figure 3.4K, p = 0.004) suggesting that CaM upregulates PO,max. Reassuringly, 
normalized Qon and Qoff were similar in magnitude in the presence of CaM and β2A-CaM (Figure 
3.4H and Figure 3.4L). In like manner, overexpression of stac3 also resulted in enhanced Itail / qrev 
(p = 0.006) for CaV1.1 (Figure 3.4M-P). These results indicate that both CaM and stac upregulates 
the maximal PO of CaV1.1 (Figure 3.4Q). Reassuringly, further quantification of gating charge 
density at +80 mV (Qdensity(+80)) shows significant increase for β2A-CaM (p = 0.039) and stac3 (p 
= 0.045), confirming modulatory agents also enhance trafficking of CaV1.1 to the plasma 
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membrane (Figure 3.4R). Together, these data suggest that both modulators not only boost surface-
membrane expression, but also upregulate the activity of CaV1.1. The CaM-dependent change in 
maximal PO is reminiscent of findings with related CaV1.3 channels (Adams et al., 2014).  
Myopathy-associated stac3 mutants diminish CaV1.1 surface-membrane trafficking – 
Recent genetic screens have identified multiple mutations within the stac3 gene that are associated 
with severe congenital myopathies as illustrated in Figure 3.5A. The first autosomal recessive 
mutation observed in patients of the Lumbee Native American tribe were homozygous missense 
mutation (W[284]S) in the first SH3 domain of stac3 (Stamm et al., 2008). Subsequently, 
compound heterozygous variants (K[288]* and L[111]Δ) were identified in a patient of Turkish 
heritage (Grzybowski et al., 2017). Given that stac3 binds to the CaV1.1 CT, we considered 
whether myopathy-associated mutants may disrupt this interaction and diminish surface-
membrane trafficking.  
 Using FRET-two hybrid assay, we assessed the binding of Ven-tagged CaV1.1 CI and Cer-
tagged stac3 variants (Figure 3.5B). In comparison to wild-type, all three disease-associated stac3 
variants exhibited a spectrum of weakened binding affinities (Figure 3.5C; black: WT, red: mutant). 
Stac3 variants, L[111]Δ and W[284]S, showed a nearly 10-fold weakened affinity while the 
mutation K[288]* resulted in a 2-fold reduced binding of CaV1.1 carboxy-terminus (Figure 3.5J). 
To discern analogous functional changes, we compared the surface-membrane trafficking of 
CaV1.1BBS with wildtype or mutant stac3 in the presence of both β1A and α2δ subunits. Upon co-
expression of wildtype stac3, CaV1.1BBS showed strong QD labeling confirmed by confocal 
imaging (Figure 3.5D) and flow cytometric analysis (Figure 3.5E and Figure 3.5K) suggesting 
robust surface-membrane expression. In contrast, co-expression of stac3 variant W[284]S with 
CaV1.1BBS resulted in sharply diminished QD labeling visualized via confocal imaging (Figure 
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3.5F). Population analysis using flow cytometric analysis further confirms this result (p < 1E-5) 
(Figure 3.5G and Figure 3.5K). Likewise, analysis of two additional disease-associated stac3 
variants, L[111]Δ (p < 1E-5) and K[288]* (p < 1E-5), revealed variably diminished channel 
surface-membrane trafficking as evident from reduced ϕmax (Figure 3.5K). Quantitatively, if the 
binding of stac3 to CaV1.1BBS genuinely underlies the enhancement in channel surface-membrane 
trafficking, then this functional increase will follow a Langmuir function with the binding affinity 
of the stac-channel interaction as follows, 
  (2.19) 




max  represent the saturating surface-membrane 
trafficking limit in the presence and absence of stac3 respectively (as described in Chapter 2). For 
stac3 variants, we assume that their relative binding affinity for the CaV1.1 CI deduced from FRET 
two-hybrid binding assays (Ka,EFF) is proportional to that for the holochannel interface (Ka). This 
theoretical framework for channel trafficking mirrors individually Transformed Langmuir (iTL) 
analysis previously developed to deduce binding interfaces critical for channel gating (Ben Johny 
et al., 2013). Plotting the experimentally determined saturating surface-membrane trafficking ratio 
ϕmax versus the relative CaV1.1 CI binding affinities (Kd,EFF) for the stac3 variants reveals the 
predicted Langmuir relationship (Figure 3.5I). These results demonstrate that stac3 binding to 
CaV1.1 promotes plasmalemmal trafficking and myopathy-associated stac variants exhibit 
weakened trafficking resulting from disrupted binding to the CaV1.1 CT.  
 Given that both CaM and stac3 independently enhance surface-membrane trafficking of 
CaV1.1, we next investigated whether CaM might rescue the defects in trafficking associated with 
myopathy-associated stac3. Consequently, we assessed surface-membrane trafficking of 












increase in QD labeling (Figure 3.5H) and flow-cytometry confirms this partial rescue at a 
population level (p < 1E-5) (Figure 3.5I). Similar analysis with other myopathy-associated stac3 
variants (L[111]Δ and K[288]*) further confirmed the partial rescue of CaV1.1BBS trafficking when 
CaMWT is coexpressed (p < 1E-5 for both variants) (Figure 3.5K). Intriguingly, the net magnitude 
of CaM-dependent enhancement in CaV1.1 surface-membrane trafficking is similar in the presence 
of all stac3 variants irrespective of their binding affinities (Figure 3.6). These results suggest that 
the CaM effect on channel trafficking is independent of stac consistent with the two regulatory 
proteins utilizing distinct binding interfaces (Figure 3.6). These results also suggest that CaM-
delivery to CaV1.1 furnishes an orthogonal strategy for rescue of functional defects resulting from 
myopathy-associated mutations in stac3. Moreover, CaV1.1 CT represents a prime interface for 
screening small-molecules that promote CaV1.1 trafficking and function.  
Small-molecule modulators reverse myopathy-associated CaV1.1 trafficking defects –  
Recently, pharmacological chaperones have emerged as a promising strategy to rescue surface-
membrane trafficking deficits observed in a variety of genetic disorders involving both G-protein 
coupled receptors (Beerepoot et al., 2017) and ion channels such as CFTR (cystic fibrosis 
transmembrane conductance regulator) associated with cystic fibrosis (Hanrahan et al., 2013), 
KATP channels associated with congenital hyperinsulinism of infancy (Martin et al., 2013), and 
NaV1.5 channels associated with Brugada syndrome (Moreau et al., 2012; Valdivia et al., 2004). 
In many of these cases, small molecule modulators that alter channel gating may offer a dual-
purpose as chaperones by stabilizing key channel conformations. Moreover, as Ca2+-influx through 
CaV1.1 channels is not necessary to trigger muscle contraction, we reasoned that clinically-relevant 
small-molecule CaV1 antagonists, that traditionally block Ca2+-influx, may be repurposed to 
reverse trafficking defects of CaV1.1 observed in the presence of myopathy-associated mutant 
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stac3 (Figure 3.7A). To evaluate this possibility, bungarotoxin-labeling assay and flow-cytometric 
analysis was used to quantify drug-induced changes in CaV1.1 trafficking co-expressed with 
mutant stac3 W[284]S, the most prevalent myopathy-associated stac variant, and α2δ and β1A 
auxiliary subunits.  
We tested three L-type Ca2+-channel modulators, nifedipine, diltiazem, and verapamil 
(Figure 3.7B, cyan bars), as well as two Na channel modulators, mexiletine and ranolazine (Figure 
3.7B, blue bars), clinically-approved for various cardiovascular conditions at two concentrations 
reflecting typical low and high therapeutic plasma concentrations. Remarkably, amongst CaV 
channel modulators, incubation with verapamil resulted in ~40% recovery of CaV1.1 trafficking 
(Figure 3.7B) at low (>60%) drug concentration and ~67% recovery at high (> 80%) drug 
concentration. Diltiazem also increased channel trafficking by ~34% at high (> 80%) drug 
concentration. By contrast, incubation with nifedipine, mexiletine, and ranolazine resulted in 
minimal change (<10%) in the saturating fraction of surface-membrane channels (ϕmax) (Figure 
3.7B). Of note, in all five conditions, the total GFP fluorescence remained the same suggesting 
that the increase in the fraction of surface-membrane channels (ϕmax) observed in the presence of 
verapamil and diltiazem reflects genuine potentiation of channel plasmalemmal trafficking. 
Verapamil application increased CaV1.1 trafficking in the absence of stac3 by approximately 2-
fold (Figure 3.7B) but only increased channel trafficking in the presence of CaM and stac3 by 24% 
and 33% respectively (Figure 3.7C).  
 We also verified the functionality of these channels electrophysiologically. HEK293 
transfected with CaV1.1 and stac3 W[284]S incubated overnight with 0.5 µM verapamil displayed 
robust ionic currents (Figure 3.7D) and large gating currents (Figure 3.7E) comparable to stac3WT 
(Figure 3.7F-G) following acute wash off of verapamil. To probe whether drug-mediated 
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enhancement in trafficking is reversible, we incubated CaV1.1 co-transfected with stac3 W[284]S 
in verapamil for 24 h, and subsequently washed off the drug for 24 h. Intriguingly, while cells 
continually incubated in drug showed ~30% increase in trafficking (Figure 3.7H; p < 1E-5), wash 
off of verapamil saw a reversal of channel trafficking (Figure 3.7H; p < 1E-5). All together, these 
results reveal plausible therapeutic potential for diltiazem and verapamil or related drugs as well 
as highlight the utility of the bungarotoxin-labeling assay for small-molecule screens of 
pharmacological chaperones. 
DISCUSSION 
CaV1.1 has often appeared atypical amongst L-type channels, with seemingly poor 
conservation of regulatory mechanisms, and idiosyncratic requirements for membrane expression 
manifesting as a loss of function in heterologous systems. While related CaV1/2 channels exhibit 
robust plasmalemmal trafficking with β and α2δ subunits, additional components such as cytosolic 
stac3 and the transmembrane γ1 subunit, are thought obligatory for CaV1.1 currents in heterologous 
systems (Bannister and Beam, 2013; Polster et al., 2016; Polster et al., 2015; Tuluc et al., 2009). 
How do these modifications at disparate channel interfaces influence trafficking?  
Our results point to a unified trafficking scheme (Figure 3.8) with the requirements for 
CaV1.1 trafficking paralleling those for related CaV channels (Fang and Colecraft, 2011). 
Specifically, the β-subunit is a dominant effector necessary for CaV1.1 plasmalemmal trafficking 
(Figure 3.8A). This requirement of β-subunits for CaV1.1 trafficking fits well with reduced channel 
expression and diminished tetrad formation observed in β1A-knockout mice (Schredelseker et al., 
2005). Upon binding the β-subunit, CaV1.1 however exhibits only low baseline trafficking (Figure 
3.8B). The binding of either CaM or stac3 alone leads to only a partial enhancement in membrane 
trafficking (Figure 3.8C-D). Finally, the binding of both CaM and stac3 to the CaV1.1 CT yields a 
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supra-linear increase in membrane trafficking (Figure 3.8E). Interestingly, complete removal of 
the CT results in a basal increase in channel trafficking suggesting that there may be retention 
motifs encoded within the CT that are masked upon the interaction of either stac3 or CaM (Figure 
3.2J). This simplified scheme captures the experimentally-observed effects of stac3 and CaM on 
CaV1.1 and provides a platform for other indirect mechanisms to be assessed.  
Mechanistically, the CaV1.1 CT is a critical determinant for surface-membrane trafficking 
by harboring both CaM and stac3, a finding that resonates with early studies that identified a vital 
role for this domain in triad localization (Flucher et al., 2000). As CaM is enriched in the triad via 
transient association with cytoplasmic loops of RyR1 (Mochca et al., 2001; Sencer et al., 2001; 
Xiong et al., 2002), its weak binding to CaV1.1 may promote co-localization of the channels at the 
tubular or surface membranes (Rodney and Schneider, 2003). Recurrent large-amplitude Ca2+-
transients in the triadic space may further reinforce this localization. Indeed, the role of Ca2+/CaM 
in mediating activity-dependent trafficking has emerged as a pervasive theme in CaV channel 
physiology, yet the precise motifs that orchestrate this phenomenon are yet to be elucidated (Hall 
et al., 2013; Tseng et al., 2017; Wang et al., 2007). Similarly, our results indicate that stac3 
potentiates CaV1.1 trafficking also via interaction with the CT. Even so, CaM and stac3 likely act 
through distinct sites as their combination supra-additively enhance channel trafficking. Analysis 
of stac3-/- zebrafish and mouse skeletal myotubes revealed a partial reduction of CaV1.1 at the triad 
leading to incomplete tetrads and a loss of EC coupling (Linsley et al., 2017a; Linsley et al., 2017b; 
Polster et al., 2015). The magnitude of reduction varied between the two models suggest that other 
regulators such as CaM may play a role in channel trafficking in the muscle. As various stac 
isoforms promote trafficking of CaV1.2 and CaV3 (Rzhepetskyy et al., 2016), stac may be a shared 
modulator across the CaV family (Weiss and Zamponi, 2017). Our quantitative framework and 
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flow-cytometric analysis of external-epitope labeling may delineate vital signals for membrane 
trafficking of CaV channels in skeletal muscle and other native cell types. 
Furthermore, stac3 co-expression upregulates the baseline PO of CaV1.1 to the same extent 
as CaM depending on the CI module (Figure 3.4O). Interestingly, in skeletal myotubes, 
homozygous stac3 knockout (Linsley et al., 2017a; Polster et al., 2015) and CaV1.1 mutants with 
weakened CaM binding (Stroffekova, 2011) lead to a dramatic loss of EC coupling despite the 
presence of gating charge movements. Thus, robust EC coupling may require a permissive CaV1.1 
CT conformation along with that for the II-III loop (Tanabe et al., 1990a). Synthesizing a general 
framework of CaV modulation by CaM and stac is an exciting frontier and the ability to express 
CaV1.1 in heterologous systems under a wide-range of conditions facilitates this pursuit and will 
be further discussed in Chapter 4.  
Pathophysiologically, our analysis reveals that disease-associated stac3 variants weaken 
binding to the CT resulting in variably diminished CaV1.1 surface-membrane trafficking, 
highlighting potential pathogenic mechanisms. Indeed, reconstitution of myopathy-associated 
mutant stac3 (W[284]S) in stac3-/- knockout zebrafish and mouse models led to diminished 
trafficking, triadic organization, and activity of CaV1.1 resulting in marked loss of EC coupling 
(Linsley et al., 2017a; Linsley et al., 2017b; Polster et al., 2016). As Ca2+-influx through CaV 
channels is not necessary for EC coupling (Dayal et al., 2017), our findings suggest that diltiazem 
and verapamil, traditionally used as CaV channel antagonists, may be repurposed as 
pharmacological chaperones that rescue trafficking defects for stac3-associated congenital 
myopathies, although this effect is contingent upon continual exposure to the drug. Diltiazem and 
verapamil are clinically prescribed for various diseases including hypertension, arrhythmia, angina, 
and cluster headaches. Side-effects presented include headaches, hypotension, gingival 
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hyperplasia, constipation, and edema. Consequently, we show that low therapeutic plasma 
concentration is sufficient for strikingly enhanced surface-membrane trafficking of CaV1.1 and 
gating charge movement remains unimpaired. Indeed, similar pharmacological chaperones have 
emerged as a potential therapeutic avenue for rescue of trafficking deficits associated with cystic 
fibrosis (Hanrahan et al., 2013), congenital hyperinsulinism of infancy (Martin et al., 2013), and 
Brugada syndrome (Moreau et al., 2012; Valdivia et al., 2004). 
These results highlight the utility of reconstituted CaV1.1 channels in HEK293 cells as a 
simplified platform to distinguish distinct regulatory effects of individual triadic signaling 
molecules, and as an attractive venue for high-throughput screens of small molecules that modulate 
CaV trafficking. Our findings illustrate that CaV1.1 trafficking and gating are tuned by redundant 
signaling mechanisms and shed light upon pathophysiological mechanisms and strategies for 




Figure 3.1. Robust expression of CaV1.1 is dependent on its carboxy-tail and binding to CaM and 
stac3.  
(A) CaV1.3 with β2a and α2δ auxiliary subunits exhibit robust currents in HEK293 cells. Top, 
cartoon depicts the CaV1.3 pore-forming α1 subunit with auxiliary subunits co-transfected. Middle, 
exemplar current traces in response to a voltage-step protocol from -80 mV to +50mV. Gray 
dashed line, baseline of 0 pA. Bottom, population data for current density-voltage relationship 
from -30 to +80 mV in 10 mV increments for indicated number of cells (n). Gray solid line, 
baseline of 0 pA.  
(B) CaV1.1 with auxiliary subunits do not exhibit functional expression. Format as in panel A.  
(C) Chimeric CaV1.1 with the CaV1.3 CT partially rescues functional expression. Format as in 
panel A.  
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(D-E) Restoration of CaM binding to CaV1.1 through overexpression of CaM or direct linkage to 
the auxiliary β2A-subunit produces robust functional expression. Format as in panel A. 
(F) Co-expression of stac3 also elicts robust Ca2+ currents through CaV1.1. Format as in panel A.  
(G) Left, schematic show FRET binding pairs, Cer-CaMWT and Ven-CaV1.3 CI. Here, the CI 
module consists of the dual vestigial EF hand, pre-IQ and IQ segments of carboxy-tail. Right, the 
CI region of CaV1.3 binds well to Ca2+/CaM (Kd,EFF = 8000 Dfree units ~ 260 nM). FRET efficiency 
(EA) is plotted as a function of donor-fluorophore tagged molecule (Dfree) concentration (right). 
Gray dashed line indicates baseline for no binding.  
(H) CaV1.3 CI binds well to apoCaM (Kd,EFF = 3000 Dfree units ~ 98 nM). Format as in panel G. 
(I) The CI region of CaV1.1 binds weakly to Ca2+/CaM. Format as in panel d (Kd,EFF = 70000 Dfree 
units ~ 2.3 μM). Format as in panel G. 
(J) CaV1.1 CI also binds poorly to apoCaM. Format as in panel G. 
(K) Stac3 binds to the CI region of CaV1.1 (Kd,EFF ~ 12000 Dfree units ~ 400 nM). Format as in 
panel G. 




Figure 3.2. CaV1.1 surface-membrane trafficking is enhanced by CaM and stac3.  
(A) Both CaV1.1 and CaV1.1BBS yield similar Ca2+ currents when co-expressed with β2a-CaM. Left, 
cartoon of CaV1.1BBS transfected with α2δ subunit and β2a-CaM. Middle, exemplar trace of current 
elicited with a +50 mV voltage-step. Right, Jpeak (mean ± SEM) computed from indicated number 
of cells (n). Format as in Figure 3.1A. 
(B) CaV1.1 in the presence of α2δ and β2A auxiliary subunits traffics poorly and exhibits weak 
extracellular labeling. Left, schematic shows external-epitope labeling of GFP-tagged CaV1.1 
engineered with an α-bungarotoxin binding site (CaV1.1BBS) in the presence of α2δ and β2A 
auxiliary subunits. Here the external epitope is α-bungarotoxin conjugated to QD. Right, 
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transmitted-light, intracellular GFP (SG), extracellular QD (SR), and merged images for transfected 
and labelled cells were collected by confocal microscopy.  
(C) Flow-cytometric analysis confirms weak surface-membrane expression for CaV1.1BBS with 
α2δ and β2A auxiliary subunits co-transfected. QD fluorescence, SR, is plotted as a function of GFP 
fluorescence, SG. Each dot represents one cell. Black dashed line indicates no extracellular labeling 
(SR = 0). Black circles and fit denote binned data for QD and GFP fluorescence fitted a single-
exponential function.  
(D-E) Confocal imaging and flow cytometry experiment show that co-transfection of β2a-CaM 
augments CaV1.1 surface-membrane labeling. α2δ was co-transfected. Format as in panels a and b. 
Blue circles and fit in panel d correspond to binned data while black fit is reproduced from panel 
b to facilitate comparison with baseline CaV1.1 trafficking.  
(F-G) Confocal imaging and flow-cytometry of CaV1.1BBS co-transfected with stac3, β2A and α2δ 
subunits confirms enhanced surface-membrane trafficking of CaV1.1 when bound to stac3. Format 
as in panels a-b.  
(H) CaV1.1BBS co-expressed with only auxiliary β1A and α2δ subunits traffic to the plasma 
membrane. Format as in panel B. 
(I) Bar graph shows surface-membrane trafficking limit ϕmax for CaV1.1BBS with β1A and α2δ 
subunits increases and stabilizes after multiple days of transient transfection. 
(J) Bar graph summarizes saturating surface-membrane trafficking limit ϕmax, proportional to the 
maximal fraction of CaV1.1 trafficked to the plasma-membrane, under various conditions as 
indicated.  denotes p<1E-5 with Welch’s T-test compared to CaV1.1 expressed with β1A. * 




Figure 3.3. CaM and stac3 bind to distinct sites on the CT and exert independent trafficking effects.  
(A) FRET binding of Ca2+/CaM with EF hands (left), pre-IQ (middle), and IQ domain (right) 
shows weak binding for EF hands and strong binding for pre-IQ and IQ domains.  
(B) Bar graph summary of binding affinities from panel A.  
(C-D) Stac3 binds preferentially to EF hands. Format as in panels A and B.  
(E-F) Coexpression of CaM and stac3 results in a distinct extracellular labeling and supralinear 
increase of channels on the membrane. Format as in Figure 3.2B-C.  
 (G) Bar graph summarizing ϕmax for CaM and stac3 separately as well as together. Expressing 
CaM and β2A-CaM does not result in a large change of ϕmax in comparison to a 6-fold increase 




Figure 3.4. PO of CaV1.1 is increased with CaM and stac3.  
(A) CaV1.1 with only its auxiliary β2A and α2δ subunits elicit small tail current (Itail) despite large 
gating charge movement indicating a low-PO for these channels at baseline. Top, cartoon depicts 
CaV1.1 α1 subunit bound to auxiliary β2A and α2δ subunits in HEK293 cells Bottom, exemplar 
currents elicited in response to voltage step-depolarization from -80 mV to +80 mV show large 
gating-charge movement at the reversal potential (qrev) and Itail evoked upon repolarization to 0 
mV.  
(B) Exemplar current trace for gating charge movement after pore block with Cd2+/La3+ with 
voltage step-depolarization from -80 mV to +80 mV and back to -80 mV. Trace shows equivalent 
gating charge movement into the open conformation (QON) and gating charge movement into the 
closed conformation (QOFF).  
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(C) Population data of Itail/qrev reveals low PO. Here, Itail evoked in response to a voltage-step family 
with varying pre-pulse potentials are normalized by the gating charge movement at the reversal 
potential, qrev. This ratio (Itail/qrev) is proportional to PO of the channel.  
(D) Population data of normalized QOFF to QON confirms equivalent charge movement and also the 
reliability for approximating PO.  
(E-H) Overexpression of CaM enhances the ratio of Itail / qrev arguing that CaM enhances baseline 
PO of CaV1.1. Format as in panels a-d. (I-L) Similarly, localized-delivery of CaM via fusion to the 
β2A-subunit enhances Itail despite similar qrev. Format as in panel A-D.  
(M-P) Co-expression of stac3 also increases Itail / qrev by approximately 5-fold, which is 
comparative to CaM. Format as in panel A-D. 
(Q) Population data of Itail (+80 mV) / qrev shows significant increase of PO with the addition of 
CaM or stac3. * for p<0.01.  
(R) Population data of Qdensity (+80 mV) confirms increase of channels on the membrane with the 
addition of CaM or stac3. * for p<0.05. 
(S) The Q-V curves (Figure 3.4D, H, L, P) were fit with double Boltzmann relations. Plot compares 
half-activation potentials for the two components (V1/2,a and V1/2,b) for various conditions. For each 
component and across all conditions, we did not observe a statistically significant difference 
between Qon (red) and Qoff (black) (p > 0.15). Moreover, no statistically significant differences 
were observed for V1/2,a and V1/2,b values in the presence of different modulators (p > 0.1). These 
results suggest that both Stac3 and CaM spare voltage-sensor movement. The profound difference 
in saturating Itail/Qrev in the presence of CaM and Stac3 would indicate that these regulatory 




Figure 3.5. Myopathic stac3 mutations reduce binding to the CT and surface membrane trafficking.  
(A) Amino acid sequence for stac3 mutations in both the C1 and first SH3 domain (SH31).  
(B) Schematic shows fluorophore tagged FRET pairs, Ven-CI of CaV1.1 with Cer-tagged stac3 
variants.  
(C) Myopathy-associated stac3 variants weaken binding to CaV1.1 CI. Left, intron insert results in 
a frameshift and truncation of SH3 domains (L[111]Δ) dramatically reduces stac3 binding to 
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CaV1.1 CI. Middle, a point mutation in the 1st SH3 domain (W[284]S) strongly reduces stac3 
binding.  Right, disease-associated stac3 variant with a nonsense mutation in the 2nd SH3 domain 
(K[288]*) moderately weakens binding to CaV1.1.  
(D) Stac3 strongly enhances CaV1.1 surface-membrane trafficking in the presence of β1A and α2δ 
subunits, as demonstrated by detectible BTX-labeling in exemplar confocal images. Format as in 
Figure 3.2B.  
(E) Flow cytometric analysis confirms high expression of CaV1.1 when bound to stac3. Format as 
Figure 3.2B.  
(F-G) Co-expression of myopathy-associated stac3 mutant (W[284]S) results in only modest 
enhancement in CaV1.1 surface-membrane trafficking as illustrated by confocal imaging and flow 
cytometry. Format as in panels D and E respectively.  
(H-I) Co-expression of CaM with mutant stac3 (W[284]S) results a large increase of CaV1.1 
surface membrane trafficking comparable to that with wildtype stac3. Format as in panels D and 
E.  
(J) Bar graph summarizes binding affinities of stac variants to CaV1.1 CI, average ± SEM.  
(K) Bar graph summarizes the saturating surface-membrane trafficking limit ϕmax of CaV1.1 in the 
presence of myopathy-associated mutant stac3 and corresponding rescue with CaM. Stac3 
mutations that weaken binding to CaV1.1 CT also reduces surface-membrane trafficking (gray bar) 
and may be partially rescued with CaM co-expression (green bar). Control (white) bar is CaV1.1 
expressed with basic auxiliary subunits α2δ and β1A for comparison.  
(L) For all stac3 variants, plotting ϕmax versus the association constant (Ka,EFF = 1 / Kd,EFF; panel C) 
for the binding of mutant stac3 to CaV1.1 CI module reveals a Langmuir relationship suggesting 
that the binding of stac3 is a key determinant for Cav1.1 surface-membrane trafficking. Dashed 





Figure 3.6. Extended analysis of CaM-dependent enhancement in CaV1.1 plasmalemmal 
trafficking in the presence of stac3 variants suggests distinct binding interfaces.  
(A) If CaM and stac3 share a common interface, then in the presence of high-affinity stac3 variants, 
CaM is incapable of reaching this interface and the effective enhancement in trafficking due to 
CaM would be minimal. However, if stac3 variants have a low affinity, then the shared interface 
is unoccupied and available for CaM.  
(B) Simulation shows CaM-dependent enhancement in CaV1.1 trafficking in the presence of 
various stac3 variants as a function of stac3 binding association constant for CaV1.1 CI (Ka,EFF 
(stac variant)). Specifically, 
η ( CaM | stac3variant ) = 
( max max(stac3 variant + CaM) -  (basal)  )/( max max(stac3 variant) -  (basal)  ). 
Dashed line corresponds to no enhancement in plasmalemmal trafficking with CaM. Blue curves 
are simulations obtained at low levels of CaM, while cyan and green are relations at high levels of 
CaM. Experimental data shows that η (black dots) is relatively constant as a function of Ka, EFF 
(stac variant).  
(C) If CaM and stac3 utilize distinct interfaces, then CaM will be able to enhance CaV1.1 
trafficking irrespective of stac3 binding status. Moreover, in this scenario the magnitude of CaM-
dependent enhancement of CaV1.1 trafficking in the presence of stac3 variants should equal the 
net increase in CaV1.1 trafficking by CaM in the absence of stac3.  
(D) Black line shows expected outcome for η (CaM | stac3 variant) if CaM and stac3 use distinct 
interfaces. Reassuringly, the experimentally-determined η values match the predicted relationship 




Figure 3.7. Small-molecule modulators partially rescue pathological deficits in CaV1.1 trafficking.  
(A) Cartoon schematizes potential enhancement of CaV1.1 plasmalemmal trafficking in the 
presence of potential pharmacological agents. Left, CaV1.1 when bound to myopathy-associated 
mutant stac3 (W[284]S) and α2δ and β1A subunits traffics poorly to the plasma membrane. Right, 
addition of a small-molecule trafficking modulator may enhance the fraction of surface-membrane 
channels.  
(B) Bar graph summarizes changes in the saturating surface-membrane trafficking limit (ϕmax) of 
CaV1.1 trafficking following addition of various small-molecule modulators at low and high 
concentrations. Lower dashed line corresponds to baseline trafficking with myopathic stac3 
(W[284]S) (gray) while upper dashed line corresponds to CaV1.1 trafficking with wildtype stac3. 
Both diltiazem and verapamil markedly enhanced ϕmax while dihydropyridines and Na channel 
modulators ranolazine and mexiletine did not substantially alter CaV1.1 trafficking. Without stac3, 
1 µM verapamil increased CaV1.1 trafficking by approximately 2-fold.  
(C) Bar graph summarizing drug effects on CaV1.1 trafficking transfected with CaMWT and 
stac3WT. Asterisk indicates statistically significant differences (p < 1E-6). 
(D) CaV1.1 expressing stac3 W[284]S are functional after incubation with 0.5 µM verapamil. Top, 
given a voltage step-depolarization from -80 mV to +50 mV, channels produce robust inward 
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current. Bottom, population data of current density-voltage relationship from -30 to +80 mV in 10 
mV increments for indicated number of cells (n). Gray solid line, baseline of 0 pA.  
(E) Gating charge movement of these channels also appear normal after pore block with Cd2+/La3+. 
Format as in Figure 3.4B. 
(F) Population data summarizing QON and QOFF for stac3WT and stac3 W[284]S. Left, QON for stac3 
W[284]S (red) is overlaid on top of QON for stac3WT (gray). Right, QOFF for stac3 W[284]S (red) 
is overlaid on top of QOFF for stac3WT (gray).  
(G) Population data summary of maximal Qdensity for stac3WT and stac3 W[284]S. 
(H) Bar graph summarizing CaV1.1 co-expressed with stac3W[284]S incubated with and without 1.0 
µM verapamil for 48 h and with wash after 24 h. Asterisk indicates statistically significant 
difference (p < 1E-6). 
 
Figure 3.8. Molecular determinants for CaV1.1 functional expression.  
Schematic illustrates a simplified model for the effect of various regulatory protein on CaV1.1 
functional expression. For all panels, top and bottom rows identify the regulatory input and 
functional outcomes respectively. Middle row schematizes underlying molecular mechanism.  
(A) Devoid of a β subunit, CaV1.1 fail to traffic to the surface membrane presumably due to ER 
retention motifs.  
(B) Binding of the β subunit enables low basal CaV1.1 surface-membrane trafficking. Channels at 
the plasma-membrane feature a low PO.   
(C) CaM enhances CaV1.1 surface-membrane trafficking. The same CaM also enhances baseline 
PO.   
(D) Stac3 binding enhances CaV1.1 surface-membrane trafficking and upregulates baseline PO.  
(E) Binding of CaM and stac allows for high CaV1.1 trafficking. The channels are presumed to 




     CHAPTER 4      
Stac selectively tunes Ca2+-regulation of CaV1 ion channels  
 
  High-voltage activated calcium (Ca2+) channels (CaV1 and CaV2) support many vital 
physiological processes including muscle contraction, neurotransmission, and gene 
transcription(Berridge et al., 2000; Clapham, 2007; Maier and Bers, 2002). In the past few decades, 
it has been shown that despite these vastly different physiological roles, CaV1 and CaV2 possess 
high sequence homology within an ~150 residue stretch in the carboxy-tail (CT) known as the 
Ca2+-inactivating (CI) module(Ben-Johny et al., 2015; Findeisen and Minor, 2010). This CI region 
interacts with a Ca2+-binding protein, calmodulin (CaM), to confer dynamic Ca2+-dependent 
regulation to CaV1 and CaV2. Furthermore, misregulation of Ca2+ through CaM signaling to the CI 
has been implicated in cardiac arrhythmias(Limpitikul et al., 2014; Mahajan et al., 2008; Venetucci 
et al., 2012; Zimmer and Surber, 2008) as well as neurological and neuropsychiatric disorders 
(Adams and Snutch, 2007; Striessnig et al., 2010; Zamponi, 2016). Subsequently, the challenge 
arises for how biology tunes CaM-regulation of these structurally similar tail elements to produce 
diverse cell signals. One way for cells to achieve this is through specialized gene expression 
patterns. In ventricular myocytes, the CaV isoform CaV1.2 is the predominant channel expressed 
throughout the cell(Mikami et al., 1989) while in Purkinje neurons, CaV2.1 is the principal channel 
expressed(Mintz et al., 1995). Another way to generate diversity in activity is by adding an extra 
layer of regulatory proteins that tune CaV function through interactions with other parts of the 
channel itself. More recently, SH3 and cysteine rich domain (stac), has been identified as a 
potential partner for CaV(Polster et al., 2015; Suzuki et al., 1996).  
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In this chapter, we leverage synergistic insights from CaV channels and demonstrate that 
stac selectively suppresses Ca2+-regulation of CaV1. In depth functional analysis demonstrates that 
stac attains this selectivity via an allosteric mechanism that exploits a distinct binding site from 
CaM, as discussed in Chapter 3 for CaV1.1, to lock CaV1 into a persistent high open probability 
(PO) gating mode. In so doing, we further identified a minimal motif that recapitulates stac 
modulation of CaV1 gating. In all, our findings identify a general class of auxiliary proteins that 
specifically intercept CaM signaling to individual targets, allowing spatial and temporal 
orchestration of Ca2+-feedback.  
RESULTS 
Stac selectively suppresses Ca2+-feedback of CaV1 channels – To contextualize plausible 
physiological roles of stac, we immunohistochemically assessed the expression and localization of 
stac isoforms in neurons and cardiac myocytes by using stac1 and stac2 specific antibodies (Figure 
4.1A). Staining coronal slices of mouse cortex with stac1 antibody showed labeling within neurons, 
consistent with reports of stac1 and stac2 mRNA in cortical neurons (Figure 4.1B) (Nelson et al., 
2013). Similar analysis of acutely dissociated adult guinea pig ventricular myocytes (aGPVMs), 
however, showed no labeling of stac1 (Figure 4.1C). By contrast, aGPVM staining with stac2 
antibody revealed low levels of stac2 labeling (Figure 4.1C) with weak t-tubular localization 
(Figure 4.1D-E). These results suggest that stac may be a regulator of both neuronal and cardiac 
ion channels.  
Thus assured, we sought to determine whether stac is a selective modulator of CaV1, CaV2, 
or NaV1 channels in heterologous systems. Accordingly, Figure 4.2A shows baseline effects of 
stac on CaV1.2 (Polster et al., 2015). Devoid of stac, CaV1.2 exhibits CaM-mediated CDI 
manifesting as enhanced decay of Ca2+ (red) versus Ba2+ current (black) when elicited using a step 
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depolarization (top panel). As Ba2+ binds CaM poorly (Linse and Forsen, 1995), Ba2+-currents 
furnish a convenient baseline measure of voltage-dependent inactivation without CDI. Upon 
coexpression of stac2, CDI is eliminated (Figure 4.2C). To quantify steady-state inactivation, we 
measured the fraction of peak Ca2+ and Ba2+ current remaining after 300-ms depolarization, rCa 
and rBa (Figure 4.2A-B, bottom panels). The strength of CDI is quantified as CDI300 = 1 – rCa / rBa, 
the fractional Ca2+-dependent component of inactivation. Thus quantified, the population data 
confirms the strong reduction in CDI of CaV1.2 upon co-expression of stac2 (p = 3.6×10-5; Figure 
4.2E). Further analysis demonstrates that both stac1 and stac3 isoforms also suppress CDI (p = 
2.0×10-5 and 7.1×10-5 respectively, Figure 4.2B, D, E). Similarly, CaV1.3 short variant (CaV1.3S), 
a close homolog of CaV1.2, also exhibits strong baseline CDI that is suppressed upon co-expression 
of stac2 (Figure 4.2F, H, J). Generalizing this phenomenon, both stac1 and stac3 isoforms also 
diminish CDI of CaV1.3 (Figure 4.2G, I, J). In like manner, we tested the effect of stac2 on 
CaV1.443*, a splice variant of CaV1.4 that exhibits robust CDI (Figure 4.2K) (Tan et al., 2012).  
Remarkably, stac2 strongly diminished CDI of CaV1.4 (p = 3.2×10-5; Figure 4.2L-M). In all cases, 
voltage-dependent inactivation is minimally perturbed by the presence of all three stac isoforms 
(Figure 4.2) while Ca2+-regulation of CaV1 is potently suppressed.  
Encouraged by its pervasiveness, we considered whether stac alters Ca2+-dependent 
modulation of CaV2 isoforms abundant in the central nervous system. For CaV2.1, CaM elaborates 
both CDF and CDI (DeMaria et al., 2001; Lee et al., 2000). However, the Ca2+-sensitivity of CDI 
process is over 50-fold weaker than that of CDF casting this negative feedback beyond 
physiological bounds (Lee et al., 2015). As such, we probed whether stac tunes CDF of CaV2.1 
using a well-established prepulse protocol (DeMaria et al., 2001; Thomas and Lee, 2016). Figure 
4.3A displays wildtype CaV2.1 currents in the absence of stac2. Upon presentation of an isolated 
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test pulse to 0 mV, the activation of Ca2+ current follows a biphasic response (gray trace). 
Following a brief voltage prepulse, however, the ensuing test the ensuing test pulse yield enhanced 
Ca2+-currents with monophasic activation reflecting CDF (red trace). Further quantification 
revealed no change in CDF of CaV2.1 following the addition of stac2 in both exemplar current 
recordings (Figure 4.3B) and population data (Figure 4.3C). For CaV2.2, CaM-regulation 
manifests as a kinetically slow CDI in response to step voltage depolarization (Figure 4.3D) (Liang 
et al., 2003). Intriguingly, CDI of CaV2.2 persisted despite overexpression of stac (Figure 4.3E). 
Population data of CDI800 quantified as the enhanced reduction in peak Ca2+ versus Ba2+ current 
(1 – rCa / rBa) following 800 ms of depolarization further confirms this trend (Figure 4.3F). Lastly, 
neuronal CaV2.3 also possesses robust and recognizable CDI (Figure 4.3G). Intriguingly, strong 
CaV2.3 CDI persists despite stac2 overexpression as confirmed by exemplary traces (Figure 4.3H). 
Furthermore, population data of CDI300 shows a minor reduction that is statistically insignificant 
(p > 0.01) (Figure 4.3I). These results reveal the selectivity of stac in tuning CaM feedback to CaV1 
versus CaV2 channels.  
Given this selectivity, we tested whether stac suppresses Ca2+-regulation of NaV1 channels. 
Though all NaV1 possess a conserved CI module homologous to both CaV1 and CaV2 (Babitch, 
1990), functional CDI that bears mechanistic similarity to CaV has thus far only been identified in 
NaV1.4 (Ben-Johny et al., 2014). Unlike CaV channels, however, NaV channels do not convey Ca2+ 
influx that triggers Ca2+-feedback. As such, we used rapid photouncaging of Ca2+ to produce step-
like increase in intracellular [Ca2+]i, whose magnitude is simultaneously measured via Ca2+ 
fluorescent indicators. Figure 4.3J displays baseline Ca2+-regulation of NaV1.4 channels. As CDI 
is kinetically slow in comparison to fast inactivation of NaV channels, we applied a train of step-
depolarizations evoked at 10 Hz to probe possible Ca2+-dependent effects (Ben-Johny et al., 2014). 
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Without Ca2+-uncaging, peak NaV1.4 currents remained steady (gray dots). However, in response 
to a Ca2+ step, the peak NaV1.4 current declined rapidly revealing CDI (red envelope). Upon stac 
overexpression, a similar Ca2+ step evoked robust CDI of NaV1.4 as confirmed by exemplar traces 
(Figure 4.3K) and population data (Figure 4.3L). Overall, these results show the specificity of stac 
in tuning Ca2+-regulation of CaV1 channels.  
Stac utilizes an allosteric mechanism to suppresses CaM signaling – We sought to 
identify molecular mechanisms that underlie selective CaV1 modulation by stac. Accordingly, we 
systematically scanned candidate binding sites by using a live-cell FRET 2-hybrid assay (Erickson 
et al., 2001) to characterize binding between YFP-tagged CaV1.3 intracellular domains (Yang et 
al., 2014a) (Figure 4.4A) and CFP-tagged stac3 (Figure 4.4B). As all three stac variants suppress 
the CDI of all CaV1 channel isoforms, we chose CaV1.3 as YFP-tagged intracellular loop peptides 
are readily available and well characterized (Yang et al., 2014a), while stac3 was selected for its 
high potency in suppressing CaV1.3 CDI (Figure 4.2I). Accordingly, we quantified 33-FRET 
efficiency (EA) between FRET pairs co-expressed in individual cells. By leveraging stochastic 
expression of the FRET pairs in cells, we obtained a saturating Langmuir relation between EA and 
the free donor concentration (Dfree) allowing for estimation of relative binding affinities (Kd,EFF). 
We found that stac3 binds well to the CI region (Kd,EFF = 20697 ± 3023 Dfree ~ 0.67 ± 0.1 μM, 
Figure 4.4C). By contrast, analysis of the amino-terminus, intracellular loops between domains I 
and II (I-II loop), domains II and III (II-III loop), and domains III and IV (III-IV loop) revealed 
far weaker binding (Figure 4.4D-H). To further localize the putative binding loci, we subdivided 
the CI module into two: (1) a proximal CI segment (PCI) composed of dual vestigial EF hand and 
preIQ segments and (2) the IQ domain (IQ). Intriguingly, the YFP-tagged PCI segment bound 
stac3 with an ~10-fold higher affinity (Kd,EFF = 17725 ± 3990 Dfree ~ 0.58 ± 0.1 μM) than the 
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downstream IQ domain (Kd,EFF = 204739 ± 25465 Dfree ~ 6.67 ± 0.8 μM) (Figure 4.4C). In all, 
systematic FRET analysis reveals that stac binds to CaV1 CI relying on upstream elements 
including the dual vestigial EF hand and preIQ domains, an interface distinct from that for CaM 
(Bazzazi et al., 2013; Minor and Findeisen, 2010). 
 To test for the functional relevance of stac binding to the CaV1 CI module, we sought to 
confer stac-sensitivity to stac-insensitive channels via a chimeric approach. We turned to CaV2.3 
that lacks strong stac-mediated CDI suppression (Figure 4.3G-I), yet readily forms functional 
chimeras with CaV1 channels (Mori et al., 2008; Yang et al., 2014a). Accordingly, we replaced the 
CI region of CaV2.3 with the corresponding segment from CaV1.3 (CaV2.3/1.3CI). Devoid of stac, 
CaV2.3-1.3CI channels exhibit strong CDI driven by local Ca2+ (Figure 4.5A, C), isolated by high 
intracellular buffering. In contrast to wildtype CaV2.3, stac2 co-expression strongly attenuated CDI 
(p = 4.7×10-4, Figure 4.5B, C) suggesting that the CaV1 CI module is necessary for stac-mediated 
suppression of CDI.  
Given that both CaM and stac share the CI module as an effector site, two disparate 
mechanistic possibilities may engender functional suppression of Ca2+-regulation. First, the 
binding of stac may competitively displace Ca2+-free CaM (apoCaM) from its preassociation site. 
Second, stac may supersede CaM signaling to the channel pore via an allosteric mechanism. 
Systematic FRET analysis suggests that stac preferentially binds upstream CI elements (Figure 
4.4C) while high-affinity CaM preassociation is supported via the IQ domain (Bazzazi et al., 2013; 
Minor and Findeisen, 2010) hinting that the two modulatory proteins may bind concurrently. To 
explicitly rule out competitive displacement of CaM preassociation functionally, we covalently 
tethered CaM onto the CaV1.3 carboxy-terminus using a poly-glycine linker (CaV1.3S-CaM) (Mori 
et al., 2004; Yang et al., 2014a). This maneuver enables robust CDI (Figure 4.5D) and ensures a 
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high local concentration of CaM near the CaV1 channel extending into the millimolar range, 
sufficient to thwart even high levels of a competitive inhibitor (Mori et al., 2004). Dominant-
negative CaM1234 with its Ca2+-binding sites disabled, typically competitively displaces intact 
apoCaM from the CI module thereby resulting in a complete loss of CDI for wildtype channels 
(Figure 4.6A). However, co-expression of CaM1234 with CaV1.3S-CaM does not abrogate CDI 
highlighting the protective nature of fused CaM against competitive inhibitors (Figure 4.6B). Thus, 
if stac competitively displaces CaM, then strong CDI should persist for CaV1.3S-CaM despite over-
expression of stac. However, CDI of CaV1.3S-CaM is strongly diminished by co-expression of 
stac2 (p = 3.8×10-6, Figure 4.5E-F) and stac3 (p = 4.5×10-4, Figure 4.6C). We observed a similar 
fate for CaV1.2-CaM in the presence of stac2 (p = 1.5×10-5, Figure 4.5G-I). These results suggest 
that both stac and CaM act concurrently via distinct sites, in contradiction with a competitive 
mechanism.  
Elementary mechanisms underlying stac-regulation of CaV1 – In addition to Ca2+-
dependent regulation, apoCaM binding itself tunes the baseline gating of CaV channels (Adams et 
al., 2014). Absent stac, CaV1 lacking prebound CaM adopt a low PO gating configuration (empty 
configuration, PO/E) while apoCaM binding switches channels into a high PO gating mode (CaM-
bound configuration, PO/A) (Adams et al., 2014). Ca2+/CaM divests this initial enhancement in PO 
and returns channels into a low PO gating mode (PO/E) manifesting as CDI. The addition of stac as 
a second regulatory ligand vastly enriches this modulatory scheme (Figure 4.7A). Three distinct 
mechanistic scenarios may thus underlie suppression of Ca2+-regulation by stac as illustrated in 
Figure 4.7B: (1) stac binding may pre-inhibit or lock channels into the low PO gating configuration 
(PO/E) akin to Ca2+-inactivated channels and forestall further Ca2+-modulation, (2) stac may 
obstruct Ca2+/CaM-dependent modulation alone sparing apoCaM to freely elicit changes in 
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baseline PO switching between PO/E and PO/A, (3) stac-binding may allosterically lock channels 
into a high PO gating mode irrespective of CaM-binding status. For Scenario 3, it is possible that 
the baseline PO of CaV1.3 in the presence of stac may be distinct from that observed with CaM-
overexpressed. Importantly, the three scenarios may be distinguished at the single-molecule level 
by assessing CaV channel PO under various CaM-bound conditions using low-noise 
electrophysiology. Hence, we focused on CaV1.3 given the rich assortment of post-
transcriptionally and post-translationally modified channel variants with vastly distinct CaM 
binding affinities (Bazzazi et al., 2013; Liu et al., 2010; Singh et al., 2008). We focused on three 
variants, CaV1.3S with high apoCaM affinity, and CaV1.3MQDY and CaV1.3L with low affinities. 
These variants possess distinct baseline PO and corresponding levels of CDI and constitute a rich 
platform to unravel stac-dependent effects (Adams et al., 2014; Tan et al., 2011).  
First, we analyzed CaV1.3S in the presence and absence of stac (Figure 4.7C-E) to 
determine whether stac may promote channel entry into a low PO gating configuration. CaV1.3S is 
typically prebound to CaM at endogenous CaM concentrations given their high affinity (Adams et 
al., 2014). We employed Ba2+ as a charge carrier to estimate baseline behavior of channels without 
confounding effects of CDI. A slow voltage-ramp (shown between -50 and +40 mV) evokes 
stochastic channel openings that approximate near steady-state PO at each voltage. Stochastic 
records displayed in Figure 4.7C show channel openings as downward deflections to the open level 
(gray curves) and closures correspond to the zero-current portions of the trace. Robust channel 
openings are detected both in the presence and absence of stac (Figure 4.7C). To estimate steady-
state PO versus voltage relationship, we averaged many stochastic records to obtain a mean current 
that is divided into the open level, and averaged over multiple patches. CaV1.3S variant exhibits 
high PO in the absence of stac (Figure 4.7D) in agreement with previous studies  (Adams et al., 
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2014). Upon over-expression of stac2, the open probability remains high with an ~10 mV 
hyperpolarizing shift in the voltage-dependence of activation (Figure 4.7D). We further scrutinized 
single channel trials to assess changes in gating modes. Figure 4.8 displays ten sequential trials of 
CaV1.3 single channel activity evoked by voltage-ramps introduced at 12 sec intervals both in the 
presence and absence of stac. In the absence of stac, CaV1.3S activity switches between epochs of 
high activity and brief periods of low activity, as evident from diary plot of average PO within 
individual trails (P̄O) (Figure 4.8B). Analysis of single-trial P̄O distribution reveals a bimodal 
distribution denoting discrete high and low PO gating modes (Figure 4.7E). Upon stac 
overexpression, however, channel activity is largely high as evident from P̄O diary plots (Figure 
4.8D) and single-trial P̄O distribution (Figure 4.7E). Thus, in contradiction with scenario 1, stac 
bound channels are not preinhibited; rather, channels preferentially adopt a high PO gating mode.  
To distinguish between the second and third mechanistic possibilities, we considered 
CaV1.3 variants with weakened apoCaM binding affinity that largely reside in the low PO 
configuration (Adams et al., 2014). Accordingly, we tested the baseline PO of CaV1.3MQDY, an 
RNA-edited variant whose central isoleucine within the IQ domain is substituted to a methionine, 
(Bazzazi et al., 2013; Huang et al., 2012) and an alternative splice variant CaV1.3L containing an 
autoinhibitory domain that competitively displaces CaM (Liu et al., 2010; Singh et al., 2008). In 
the absence of stac and under endogenous CaM levels, both CaV1.3MQDY (Figure 4.7F-G) and 
CaV1.3L (Figure 4.7I-J) open sparsely, exhibiting a sharply diminished maximal PO consistent with 
channels lacking CaM (Adams et al., 2014; Bock et al., 2011). Indeed, single-channel trials of 
CaV1.3MQDY (Figure 4.9A-C) and CaV1.3L (Figure 4.10A-C) under endogenous levels of CaM 
reveal uniformly low activity with single-trial P̄O distribution restricted to low limits (Figure 4.7H 
for CaV1.3MQDY; Figure 4.7K for CaV1.3L). CaM overexpression with both channel variants, reveal 
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the resurgence of epochs of high activity (Figure 4.9D-E; Figure 4.10D-E) and a bimodal P̄O 
distribution with a substantial fraction of trials corresponding to a high PO gating configuration 
(Figures 4.7H and 4.7K for CaV1.3MQDY and CaV1.3L respectively). Upon stac co-expression, 
robust channel openings re-emerge for both CaV1.3MQDY (Figures 4.7F-G) and CaV1.3L (Figures 
4.7I-J) yielding a markedly enhanced baseline PO akin to CaV1.3S variant (Adams et al., 2014). In 
fact, scrutiny of single-channel trails for both channel variants reveal uniformly high channel 
activity (Figure 4.9F-G for CaV1.3MQDY; Figure 4.10F-G for CaV1.3L) and single-trial P̄O 
distributions are now firmly within the high activity limits (Figures 4.7H and 4.7K) reminiscent of 
the CaM overexpression. Interestingly, the steady state PO-V relations for CaV1.3S, CaV1.3MQDY 
and CaV1.3L in the presence of stac closely approximate each other with a maximal PO matching 
that for channels with prebound apoCaM (Figures 4.7D, G, and J). These findings demonstrate 
that consistent with Scenario 3, stac-binding locks CaV1.3 channels in the high PO configuration 
and effectively decouples the channel pore from CaM-dependent conformational changes. 
Moreover, these results highlight the dominance of stac over CaM in modulation of CaV1.  
U-domain constitutes a minimal motif for CaV1 CDI suppression – With elementary 
mechanisms discerned, we turned to identify stac motifs functionally-critical for allosteric 
suppression of CaM-regulation. Structurally, stac isoforms share a strikingly modular architecture 
composed of a C1 domain linked to one or two SH3 domains via a largely unstructured linker 
segment (U-linker region) (Suzuki et al., 1996). As these modular subcomponents typically 
recognize distinct ligands, we reasoned that their molecular functions may be separable (Cohen et 
al., 1995; Colon-Gonzalez and Kazanietz, 2006). Accordingly, we trisected stac2 to assess whether 
individual subcomponents can recapitulate functional regulation. We focused initially on C1 and 
tandem SH3 domains as these segments were recently shown to be critical for CaV1.1 binding and 
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triadic localization in skeletal muscle (Campiglio and Flucher, 2017; Wong King Yuen et al., 2017). 
Surprisingly, co-expression of either segment, however, only minimally perturbed CDI of CaV1.2-
CaM (Figures 4.11A, C, and D). By contrast, the linker region by itself fully abolished CDI of 
these channels (p = 8.9×10-6, Figures 4.11B, D), recapitulating the effect of stac2 on CaV1.2.  
To further localize vital functional domains within the U-linker, we undertook 
bioinformatic analysis to identify highly conserved regions. We performed multiple sequence 
alignment of complete sequences of 780 orthologs of stac isoforms using the MUSCLE algorithm 
(Edgar, 2004) and subsequently computed an empirical measure for the degree of protein sequence 
conservation at each position. The degree of conservation is defined as the likelihood of observing 
the consensus residue at each sequence position divided by the number of distinct residues 
observed at this position. By this algorithm, perfectly conserved residues will yield a unitary value 
while poorly conserved residues have a lower score. Thus probed, we identified a 22-amino acid 
stretch, termed the U-domain (‘unknown’ domain), exhibiting a high degree of conservation 
(Figure 4.11E, blue shaded region). Remarkably, coexpression of U-domain alone is sufficient to 
strongly diminish CDI of both CaV1.2-CaM and CaV1.3-CaM (Figure 4.11F-H). Thus armed, we 
undertook systematic alanine scanning mutagenesis of stac2 U-domain to identify functionally-
critical residues (Figure 4.11I; Figure 4.12). Remarkably, coexpression of mutant stac2 with triple 
alanine substitution of residues ETL[206-208] resulted in minimal disruption of CaV1.2 and 
CaV1.3 CDI (Figure 4.11J-K) suggesting that these residues are necessary for stac function. Further 
analysis also revealed residues PVY[203-205] and KVD[200-202] to be critical for stac function 
(Figure 4.11I; Figure 4.12A-C). Residues outside these loci only minimally affected stac function 
(Figure 4.11I; Figure 4.12D-G). Altogether, these findings demonstrate the necessity and 
sufficiency of the U domain as a minimal motif in suppressing CaM-regulation of CaV1 channels.  
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U-domain modulates native CaV1 and reshapes cardiac action potentials – Having 
identified minimal U-domain that fully recapitulates stac mediated CDI suppression, we sought to 
assess the physiological consequences of stac misregulation in ventricular myocytes. Accordingly, 
we synthesized the U-domain of stac2 as a peptide and delivered it via pipet dialysis to acutely 
elevate the myocyte’s cytosolic concentration. We functionally validate the synthesized peptide 
by first testing its effect on recombinant CaV1.2 expressed in HEK293 cells (Figure 4.13A). 
Following pipet dialysis of the U-peptide, CDI of CaV1.2 was strongly suppressed as evident from 
exemplar currents and population data (Figure 4.13B-C).  
 Thus affirmed, we isolated ventricular myocytes from adult guinea pigs (aGPVMs) to 
probe changes in CDI of native CaV channels and action potential duration in response to changes 
in stac levels (Figure 4.13D). Devoid of U-peptide, endogenous CaV channels in ventricular 
myocytes displayed strong CDI, establishing baseline levels of CaM-regulation (Figure 4.13E). 
Remarkably, pipet dialysis of U-peptide dramatically reduced CDI in myocytes (Figures 4.13E-F). 
The dramatic reduction in overall inactivation of CaV channels suggests that fluctuations in stac 
levels may markedly alter action potential waveforms. To explicitly test this possibility, we 
collected current clamp recordings of aGPVMs and compared action potential waveforms in the 
presence and absence of U-peptide. Figure 4.13G shows typical voltage profiles of action 
potentials in aGPVMs paced at 0.5 Hz. Waveforms are stable between traces and the mean action 
potential duration (APD80), the duration of time when the action potential is 80% repolarized, is 
277.9 ± 31.37 ms (mean ± S.E.M., n = 6). Figure 6H displays the complement of the cumulative 
distribution of APD80. When the peptide is added to the internal solution, APD80 is greatly 
enhanced to 740.1±105.49 ms (n = 6) (Figure 4.13G-H). Thus, the U-peptide both alters the CDI 
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of endogenous cardiac CaV1 and, in so doing, markedly prolongs the APD. This action potential 
prolongation may ultimately destabilize rhythmicity of the heart.  
DISCUSSION  
Though distinct physiologically, CaV1, CaV2, and NaV1 feature a modular CI element 
suggesting a common fingerprint of CaM interaction and shared mechanistic basis for Ca2+-
regulation. Our findings suggest that stac allosterically overrides CaM-signaling to CaV1 by 
locking the channel into a high PO gating mode irrespective of whether apoCaM or Ca2+/CaM is 
bound. This effectively disengages the pore from CaM-conformational changes and abolishes CDI. 
In cardiac myocytes, CDI of CaV1 is a key factor for action potential duration (Limpitikul 
et al., 2014; Mahajan et al., 2008). Experimentally, this prominence is inferred from prolongation 
of action potentials upon expression of mutant CaM1234 (Alseikhan et al., 2002). Yet, constitutive 
CaM expression may evoke nonspecific effects (Hall et al., 2013; Wang et al., 2007) that obfuscate 
the net contribution of CaV1 CDI (Ben-Johny et al., 2015). Acute elevation of the U-domain 
bypasses these ambiguities and confirms a key role for CaV1 CDI for cardiac action potentials. 
Pathophysiologically, aberrant stac expression may be also be a risk factor for arrhythmias as 
differential expression of stac2 has been reported in right ventricular heart failure hinting at a 
potential role in calcium remodeling following heart failure (di Salvo et al., 2015). 
Furthermore, we show that stac uniformly locks CaV1.3 variants into a high PO 
configuration incapable of CDI, thus abolishing diversity in gating behavior. Post-transcriptional 
modification of CaV1.3 generates an impressive array of variants with modified carboxy-termini 
(Bock et al., 2011; Huang et al., 2012) to modulate rhythmicity in suprachiasmatic nucleus (Huang 
et al., 2012), substantia nigra (Adams et al., 2014; Guzman et al., 2009) and chromaffin cells 
(Vandael et al., 2010). Notably, the functional manifestation of CaV1.3 alternative splicing is cell-
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type specific suggesting that auxiliary regulators may refine channel properties (Scharinger et al., 
2015). Consequently, resolving stac function in these settings may reveal new physiological and 
pathophysiological insights. 
Stac1 and stac2 isoforms are expressed in both hippocampal and midbrains neurons as well 
as ventricular cardiac myocytes, cell-types where endogenous CaV1 exhibit robust CDI (Bazzazi 
et al., 2013; Oliveria et al., 2012) (Figure 4.13E). As all stac variants shunted CDI of CaV1 in 
HEK293, it is possible that stac function may be tightly regulated in native settings. One possibility 
is that stac abundance may be limited either developmentally (Suzuki et al., 1996) or via interacting 
proteins (Satoh et al., 2006). Indeed, acute elevation of U-domain diminished CDI in myocytes 
consistent with low baseline stac function. Physiologically, as CaV1 CDI is a potent homeostatic 
mechanism that prevents pathological Ca2+-overload (Dunlap, 2007), a low concentration regime 
of stac may be advantageous. By modulating a subpopulation of CaV1, stac may circumvent 
homeostatic requirements to amplify local Ca2+-signals via sustained Ca2+ influx. The C1 and SH3 
domains may serve as scaffolds to localize stac to specific signaling complexes (Campiglio and 
Flucher, 2017; Cohen et al., 1995; Colon-Gonzalez and Kazanietz, 2006). Alternatively, 
phosphorylation of stac may dynamically tune its function (Huttlin et al., 2010). Resolving these 
complexities may unveil mechanisms that tune CaV function spatially and temporally. 
Interestingly, Ca2+-binding proteins (CaBPs) (Haeseleer et al., 2000) also suppress CaM 
signaling to CaV1 (Lee et al., 2002; Yang et al., 2006). Mechanistically, CaBPs exploit a mixed 
allosteric scheme – at low concentrations, CaBPs engage interfaces distinct from that of CaM and 
while at higher concentrations CaBPs displace CaM (Findeisen and Minor, 2010; Oz et al., 2013; 
Yang et al., 2014a). Like stac, CaBPs also interact with upstream CI module of CaV1 hinting at 
commonalities in regulatory mechanisms (Oz et al., 2013; Yang et al., 2014a; Zhou et al., 2005). 
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The selectivity of CaBPs in modulating CaV1, however, is yet to be resolved as CDF of CaV2.1 is 
reduced (Lee et al., 2002) though CDI of CaV2.3 is unperturbed (Yang et al., 2014a). Nonetheless, 
the existence of other regulatory proteins to curtail Ca2+-feedback points to a general class of 
auxiliary regulators of CaM-signaling and identifying such molecular players is critical to 




Figure 4.1. Stac2 is differentially expressed in cardiac myocytes and neurons. 
(A) HEK293 transfected with stac1-3 (top) and immunostained with DAPI (cyan) and stac1 (red, 
top) or stac2 (red, bottom) antibodies confirm selectivity of stac antibodies. Images representative 
of 3 field of views. 
(B) Coronal slices of mouse cortex immunostained with DAPI (cyan) and stac1 (red). Images 
representative of 5 field of views.  
(C) Acutely dissociated aGPVM immunostained with α-actinin (green) and stac1 (red, left) and 
stac2 (red, right). Images representative of 3 field of views. 
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(D) Stac2 immunostaining reveals weak t-tubular localization in aGPVM. Image reproduced from 
panel C. Yellow line, line-scan used in panel E. Images representative of 7 field of views. 
(E) Fluorescence intensity of stac2 (red, left) and α-actinin (green, left) across the line-scan shown 
in panel D from left to right. Vertical lines correspond to location of the peak fluorescence intensity 
for α-actinin. Right subpanel shows prominent spatial frequency of 0.52 µm-1 with both α-actinin 
(green) and stac2 (red).  
 
Figure 4.2. Stac abolishes Ca2+/CaM-regulation in CaV1 channels. 
Cartoon schematic of channel interrogated is shown in the left column. 
(A) CaV1.2 expressed in HEK293. Top, exemplar current traces evoked in response to +10 mV 
voltage-step shows robust CDI (rose shaded area) evident as enhanced current decay with Ca2+ 
(red) versus Ba2+ (black) as the charge carrier. Bottom, population data for the extent of steady-
state inactivation in Ca2+ (red) and Ba2+ (black), here, is estimated by the metric r300, the ratio of 
current remaining at 300ms to peak current during a depolarizing pulse, plotted as a function of 
voltage. CDI is once again shaded in rose. Each symbol, mean  SEM from specified number of 
cells (n). 
(B) Stac1 abolishes CDI in CaV1.2. Format as in panel A. 
(C) Similarly, stac2 eliminates CDI in CaV1.2. Format as in panel A. 
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(D) Finally, stac3 also reduces CDI in CaV1.2. Format as in Panel A. 
(E) Bar graph displays population data of CDI for CaV1.2 in the absence and in the presence of 
stac1, stac2, or stac3. Dashed line shows baseline CDI = 1 – rCa / rBa in the absence of stac for 
comparison. Each bar, mean ± S.E.M. obtained from specified number of cells (n).  
(F-J) Stac isoforms also suppress CDI of CaV1.3S, the canonical short variant, as confirmed by 
both exemplar traces (panel F-I) and population data (panel J). Format as in panels A-E. 




Figure 4.3. Stac does not affect Ca2+/CaM-regulation in CaV2 channels or NaV1.4. 
(A) CaV2.1 exhibits robust CDF when evaluated using a prepulse protocol. Top, an isolated test 
pulse to 0 mV elicits Ca2+ currents with biphasic activation, containing rapid and slow components 
due to a superposition of voltage activation and CDF (gray). With a +20 mV prepulse, sufficient 
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Ca2+ enters to partially facilitate channels such that the subsequent step to 0 mV has a markedly 
blunted slow component (red). The area between the two current traces (ΔQ), divided by τslow, 
yields facilitation (g). Bottom, population data for g plotted as a function of prepulse potentials 
reveals a U-shaped dependence of Ca2+-dependent facilitation. Each symbol, mean  SEM from 
specified number of cells (n). 
(B) Stac2 spares CDF of CaV2.1. Format as in panel A. 
(C) Bar graph plots, population data for CDF = gCa – gBa. Each bar, mean ± S.E.M. obtained from 
specified number of cells. 
(D-F) Stac2 spares CDI of CaV2.2 assessed in response to +30 mV test pulse. Format as in Figure 
4.1A, C, and E respectively. Here, CDI is evaluated following 800 ms, to accommodate slow 
inactivation kinetics. 
(G-I) Stac2 spares CDI of CaV2.3. Format as in Figure 4.1A, C, and E respectively. 
(J-L) Stac2 spares CDI of NaV1.4. Both in the absence and presence of stac, NaV1.4 peak currents 
decline following a Ca2+ step (rose fit) (panel J, top). Gray dots, peak currents before 
uncaging. CDI = 1 – average peak INa of last 4 responses after Ca2+ uncaging / peak INa before 
uncaging. Bar graph plots maximal CDI observed with Ca2+ steps > 5 μM (panel L). Each bar, 




Figure 4.4. Systematic FRET 2-hybrid scan of major intracellular domains of CaV1.3 with stac.  
(A) Schematic depicts design of YFP-tagged CaV1.3 intracellular loop constructs (NT, I-II loop, 
II-III loop, III-IV loop, CI region, PCI region, IQ domain). The exact sequence of the N- and C-
termini of each peptide as well as locations on the CaV1.3 α subunit are denoted.  
(B) Cartoon shows FRET pairs, CFP-stac3 with YFP-CI, YFP-PCI, and YFP-IQ of CaV1.3. 
(C) FRET-binding curves show robust binding of stac3 to both the CI and PCI segment while 
binding to IQ is weaker. 
(D-G) FRET 2-hybrid binding curves for stac3 interaction with various channel intracellular loops 
(black symbol and fit). Each symbol denotes FRET measurements from a single cell. Stac3 binds 
very weakly to the Amino terminal (NT) peptide (panel D) that includes the CaM-binding segment, 
NSCaTE. Both the I-II (panel E) and the II-III loop peptides (panel F) also showed little or no 
FRET binding. By contrast, the III-IV loop peptide bound appreciable to stac3 (panel G). 
(H) Bar graph summarizes the relative association constant, Ka,EFF, of stac3 binding to major 




Figure 4.5. Allosteric regulation of stac by interaction with the channel carboxy-terminus. 
(A-C) Transferring CaV1.3S CI to CaV2.3 (CaV2.3/1.3CI) unveils latent stac2 mediated suppression 
of CDI. Format as in Figure 4.1A, C, and E respectively. 
(D-F) Stac2 suppresses CDI of CaV1.3S tethered to CaM. Fusion of CaM protects CaV1.3S from 
competitive inhibitors such as CaM1234. Format as in Figure 4.1A, C, and E respectively. 
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(G-I) Stac2 suppresses CDI of CaV1.2 tethered to CaM. Format as in Figure 4.1A, C, and E 
respectively. 
 
Figure 4.6. Dominant-negative CaM1234 competitively abolishes CDI. 
(A) CDI of CaV1.3S is absent in the presence of CaM1234. Format as in Figure 4.1A. 
(B) Fusion of CaMWT protects CaV1.3S from CaM1234, a competitive inhibitor of CDI. Exemplar 
currents shows robust CDI of CaV1.3S-CaM under both control conditions and in the presence of 
CaM1234. These results demonstrate that CaM-fusion can protect CaV1.3 from competitive 
inhibition of CDI. Format as in Figure 4.1A. 
(C) Population data of r300 confirms the abolition of CaV1.3S-CaM CDI with stac3. Format as in 






Figure 4.7. Stac enhances the PO of CaV1.3. 
(A) A general four-state scheme for stac and CaM modulation. (1) CaV1.3S devoid of CaM and 
stac possess a low baseline PO (PO/E) (2) Without stac, apoCaM binding to CaV1.3S upregulates 
baseline PO (PO/A). Baseline PO of CaV1.3S bound to stac in the absence (configuration 3) and the 
presence of apoCaM (configuration 4) are unknown.  
(B) Schematic outline three mechanistic possibilities for stac binding to CaV1 and their functional 
outcomes. Scenario 1, stac uniformly suppresses PO of CaV1 (PO/E) and abolishes CDI. Scenario 
2, apoCaM tunes baseline PO of CaV1 despite concurrent stac binding. Stac, nonetheless, abrogates 
CDI. Scenario 3, stac uniformly upregulates the baseline PO of CaV1 and abolishes CDI (PO/A). 
(C) Cartoon shows the canonical CaV1.3S variant with a high apoCaM binding affinity. Single-
channel analysis of recombinant CaV1.3S in the absence (left) and presence of stac (right). In both 
panels, the unitary Ba2+ currents during voltage-ramp shown between -50 mV and + 40 mV 
(slanted gray lines, GHK fit). Robust CaV1.3 openings are detected in the absence and presence of 
stac. 
(D) Average single-channel PO-voltage relationship for CaV1.3S obtained from multiple patches in 
the absence (gray) and presence of stac (blue). Error bars indicate ± SEM for specified number of 
patches and 100 – 150 stochastic records per patch.   
(E) Histogram shows distribution of single-trial average PO (?̅?O) for the voltage-range -30 mV ≤ 
V ≤ +25 mV under control (top), stac-bound (middle), and CaM-bound (bottom) conditions. 
Absent stac, ?̅?O-distribution is bimodal in the absence of stac corresponding to high PO (gray) and 
low PO (rose) gating modes. With Stac, ?̅?O-distribution largely restricted to the high PO mode. 
(F – H) Single-channel analysis of recombinant CaV1.3RNA-edited variant reveals a marked 
upregulation in the baseline PO consistent in the presence of stac compared to control condition 
where apoCaM preassociation is weak. Absent stac or CaM, single-trail ?̅? O-distribution is 
restricted to the low PO limits, In the presence of stac and CaM, the high PO gating mode re-
emerges. Format as in panels C – E.  
(I – K) Stac also upregulates the baseline PO of CaV1.3L alternatively-spliced variant by stabilizing 




Figure 4.8. Stac2 preferentially biases a high PO gating mode for CaV1.3.  
(A) Cartoon schematizes CaV1.3S.  
(B) Left, ten sequential single-channel trials of CaV1.3S under endogenous levels of CaM illustrate 
high PO gating mode with rare sojourns into a low PO gating mode. Here, traces show Ba2+ currents 
elicited every 10 sec in response to a voltage ramp shown between -40 mV to +40 mV. Right, 
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Diary plot displays single trial average PO computed for the voltage-range -30 mV ≤ V ≤ +25 mV 
(?̅?O(-30 ≤ V ≤ 25)). Dashed line discriminates traces to low PO (red shaded area) or high PO (gray 
shaded area) categories as previously established.  
(C) Average PO at each voltage calculated for all traces within the high PO range (gray region in 
panel B) and the low PO range (red shaded region in panel B). These relationships estimate the PO-
V relationship for high PO and low PO gating modes. 
(D – E) In the presence of stac2, CaV1.3S preferentially adopts the high PO gating configuration. 




Figure 4.9. Stac2 and CaM enhances the PO of CaV1.3RNA-edited variant via discreet transitions into 
a high PO gating mode.  
(A) Cartoon schematizes CaV1.3RNA-edited. RNA-editing results in a methionine substitution of the 
central isoleuicine residue, resulting in sharply diminished CaM binding. Functionally, CaM 
binding enhances the PO of CaV1.3RNA-edited.  
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(B – C) Under endogenous levels of CaM, CaV1.3RNA-edited exhibits a uniformly low PO as evident 
from individual trials. The average PO – V relation is consistent with that for the low PO gating 
mode. Format as in Figure 4.8B-C.  
(D – E) CaM over-expression enhances the PO of CaV1.3RNA-edited variant. Format as in Figure 
4.8B-C. Exemplar traces depict channels switching between discrete high and low PO gating 
modes. PO-V relationship for high PO and low PO gating modes are evident.  
(F – G) Similar to CaM, stac2 over-expression also enhances the PO of CaV1.3RNA-edited variant by 
stabilizing the high PO gating mode. Format as in Figure 4.8B-C. Exemplar traces depict channels 




Figure 4.10. Stac2 and CaM enhances the PO of CaV1.3L variant.  
(A) Cartoon schematizes CaV1.3L. The long-splice variant includes a distal carboxy-tail (DCT) 
that interacts with the IQ domain and competitively displaces CaM.  
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(B – C) Under endogenous levels of CaM, CaV1.3L exhibits a uniformly low PO as evident from 
individual trials. Format as in Figure 4.8B-C. The average PO – V relation is consistent with that 
for the low PO gating mode.  
(D – E) CaM over-expression enhances the PO of CaV1.3L variant. Format as in Figure 4.8B-C. 
Exemplar traces depict channels switching between discrete high and low PO gating modes.  
(F – G) Similar to CaM, stac2 over-expression also enhances the PO of CaV1.3L variant by 
stabilizing the high PO gating mode. Format as in Figure 4.8B-C. Exemplar traces depict channels 
largely adopting the high gating mode.  
 
Figure 4.11. Stac U-domain is a minimal effect domain for suppression of CaV1 CDI. 
(A – C) To localize an effector motif for stac2, CDI of CaV1.2-CaM was quantified in the presence 
of three stac subdomains: (1) C1, (2) linker region, and (3) SH3-SH3. Exemplar traces in response 
to a +10 mV voltage-step depolarization show robust CDI of CaV1.2-CaM in the presence of C1 
(panel A), and SH3-SH3 (panel C) domains. Coexpression of the linker-region is sufficient to 
suppress CDI of CaV1.2.-CaM (panel B). Format as in Figure 4.2A-C. 
(D) Bar graph summarizes population data for CaV1.2-CaM CDI in the presence of the three stac 
subdomains. Each bar, mean ± s.e.m of CDI300 at +10 mV from specified number of cells. CDI 
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levels in the presence (solid blue line) and absence (dashed grey line) of full length stac2 is 
reproduced for comparison. 
(E) Bar graph shows degree of conservation for the linker region across 750 orthologs of stac2. A 
well conserved subsegment termed U-domain is shaded blue. 
(F–G) Co-expression of U-domain is sufficient to abolish CDI of CaV1.2-CaM (panel F) and 
CaV1.3-CaM (panel G). Format as in Figure 4.2A. 
(H) Bar graph displays population data for CDI of CaV1.2-CaM and CaV1.3-CaM in the presence 
of U-domain. Each bar, mean ± s.e.m of CDI300 at +10 mV from specified number of cells. Dashed 
line, baseline CDI for both channels in the absence of stac2. Blue line, CDI of both channels in the 
presence of full length stac2.  
 (I) Systematic alanine scanning mutagenesis of the U-domain reveals critical determinants for stac 
mediated suppression of CaV1.2 CDI. For comparison, CaV1.2 CDI in the presence (blue line) and 
absence (black dashed line) of stac2 are shown. Stac2 mutants 200KVD/AAA, 203PVY/AAA, 
206ETL/AAA fully abolish stac2-mediated CDI suppression.  
(J) Exemplar currents show that stac2 mutant 206ETL/AAA eliminates stac’s ability to suppress 
CaV1.2 CDI. Format as in Figure 4.2A. 




Figure 4.12. Systematic alanine scanning mutagenesis of minimal U-motif reveals structural 
determinants for stac modulation of CaV1.  
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(A) Triple alanine substitution of residues 200KVD202 abolishes stac modulation of CaV1.2. In 
comparison to stac2 that fully suppresses CDI of CaV1.2, co-expression of stac2 200KVD/AAA 
spares strong CDI of CaV1.2 suggesting that residues 200KVD202 is critical for stac modulation. 
Left, cartoon schematizes the location of 200KVD/AAA mutation on full length stac2. Middle, 
exemplar current traces show robust CDI of CaV1.2 in the presence of stac2 200KVD/AAA. Right, 
population data showing r300 values as a function of voltage for Ca2+ (red) and Ba2+ currents (black). 
Each symbol, mean ± SEM from 5 cells.  
(B – C) Triple alanine substitution of stac2 residues 203PVY205 and 206ETL208 abolishes stac 
modulation of CaV1.2 as evident from strong CDI present despite overexpression of mutant stac. 
Format as in panel A.  
(D – G) CaV1.2 CDI is suppressed by stac2 despite alanine substitution of residues, 209RYG211 
(panel D), 212TSL214 (panel E), 218NRS220 (panel F), and 221S (panel G) suggesting that these 
residues are not necessary for stac modulation of CaV1 channels.  Format as in panel A.  
 
Figure 4.13. Synthetic U-domain peptide is sufficient for physiological perturbations. 
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(A) Schematic illustrates pipet dialysis of custom synthesized U-domain peptide in CaV1.2 
heterologously expressed in HEK293 cells, a strategy that emulates acute elevation of cytosolic 
stac2 levels.  
(B – C) Exemplar traces and population data confirms that pipet dialysis of U-domain suppresses 
CDI of recombinant CaV1.2 in HEK293 cells. Format as in Figure 2A and 2B. 
(D – F) Pipet dialysis of U-domain abolishes CDI of endogenous L-type current in freshly 
dissociated ventricular myocytes from adult guinea pigs as evident from exemplar traces and bar 
graph summary of population data. To eliminate T-type current, the cells were depolarized to -40 
mV for a period of 100 ms.  Format as in Figures 2A and 2B.  
(G) Exemplar action potential traces of aGPVMs paced at 0.5 Hz with (blue) and without (black) 
0.5 μM U-domain in the internal solution. In the presence of U-domain, the action potentials are 
markedly prolonged (blue shaded area) consistent with a loss of CDI of native L-type current.  
(H) Complement of cumulative distribution (P(APD80 > t) of action potential durations (APD80) 




     CHAPTER 5      
Conclusions 
 
 In the previous chapters, we presented a new understanding of stac proteins in regulating 
trafficking and gating of L-type Ca2+ channels. More specifically, we explained multiple missing 
puzzle pieces for understanding CaV1.1 and show that it is not as different from other members of 
the CaV1 family as originally perceived. In particular, we show that CaM and stac act 
independently to increase channel trafficking as well as PO while exploring treatments for stac-
associated congenital myopathies. Additionally, we expanded the understanding of CaV1 
regulation by stac proteins and may now add a new class of auxiliary proteins to our general 
knowledge of ion channels known as selective allosteric regulators. 
The prodigal child returns home – Although CaV1.1 was one of the first voltage-gated 
Ca2+ channels cloned from the genome (Tanabe et al., 1987), it was still viewed as “different” 
because many were unable to interrogate its biophysical properties reliably in heterologous 
systems. While general assumptions held this to be a result of a decrease in trafficking, it was 
difficult to determine the validity of this postulation as there are no dependable antibodies for 
visualizing these channels on the cell membrane. Similarly, CaM regulation of CaV1.1 evaded 
consensus for many decades as there was no easy method to probe this phenomenom. While 
exogenously expressed CaM localizes to the skeletal muscle triad (Rodney and Schneider, 2003), 
CaM interaction with CaV1.1 has been controversial in biochemical studies. Some report weak to 
no binding (Ohrtman et al., 2008), while in vitro surface plasmon resonance measurements and 
crystallographic analysis suggest a high-affinity interaction with the channel carboxy-tail (CT) in 
the presence of Ca2+ (Black et al., 2005; Halling et al., 2009; Sencer et al., 2001). Similarly, 
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functional analysis of CaV1.1 in skeletal myotubes revealed ultra-slow and variable extent of CDI 
casting doubt as to whether CaM is relevant for CaV1.1 function (Ohrtman et al., 2008; Stroffekova, 
2008; Tanabe et al., 1990b) while mutations of the CaM binding interface in the CaV1.1 CT 
strongly reduce EC-coupling despite the presence of gating charge movements (Stroffekova, 2011). 
Using external-epitope labeling, it is possible to see that CaV1.1 does indeed traffic to the 
plasma membrane though at a slower rate (Figure 3.2I-J). It is also possible to collect 
electrophysiological data from these channels when channel trafficking appears to plateau on the 
second day (Figure 3.4A). While stac does enhance channel trafficking by four- to five-fold (Figure 
3.2J), it also enhances gating by approximately five-fold (Figure 3.4O). This enhancement in 
gating makes electrophysiology much easier while channel trafficking is most likely more 
important for the physiological function of skeletal muscle contraction as the influx of Ca2+ is not 
necessary for muscle twitches (Armstrong et al., 1972; Dayal et al., 2017).  
Furthermore, CaM regulation of CaV1.1 may not be as different as originally thought. For 
nearly all CaV1 and CaV2 channels, CaM confers a potent feedback mechanism (Ben-Johny et al., 
2015; Halling et al., 2006; Minor and Findeisen, 2010). Our analysis shows that local enrichment 
of CaM to CaV1.1 also results in a 5-fold increase in maximal PO (Figure 3.4K). As potentiation 
in gating occurs at high-voltages where channels convey minimal Ca2+-influx, this effect likely 
depends on apoCaM interaction. Excitingly, these results are evocative of recent findings that 
apoCaM binding augments the baseline PO of CaV1.3 variants (Adams et al., 2014) hinting at a 
conserved mechanism across the CaV superfamily (Ben-Johny et al., 2015). Of note, effects on 
channel gating and trafficking were both elicited by CaM fused to β-subunit. As β-subunits have 
a 1:1 stoichiometry with the α-subunit (Dalton et al., 2005; Wu et al., 2016), a single CaM mediates 
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both functional effects. Thus, CaM signaling may be bifurcated whereby the apo-form enhances 
channel gating while the Ca2+-bound form enriches channels at the plasma membrane.  
Other studies on an embryonic splice variant have also shown that due to the long linker 
between the S3-S4 transmembrane segments of domain IV, CaV1.1 currents are much smaller and 
possess slower activation kinetics (Tuluc and Flucher, 2011; Tuluc et al., 2009). Intriguingly, 
chimeras of CaV1.3 with CaV1.1 CI (CaV1.3-CaV1.1 CI) display robust CDI while the addition of 
stac abolishes this CDI (Figure 5.1). Altogether, these results suggest that CaM does interact with 
CaV1.1 in a fashion similar to other CaV channels. Instead, the observed differences in biophysical 
properties may be a result of an evolutionary lack of need for Ca2+ signaling to RyR1 and an 
emphasis on fine-tuning channel conformational changes propagated to RyR1 in response to 
neuronal firing. 
Towards pathophysiology and treatment of myopathy-associated stac mutants – While 
stac3 is implicated in the biophysical properties of CaV1.1, it has been pathophysiologically 
identified as a vital genetic locus for a debilitating congenital myopathy that encompasses an 
expanding list of mutations. Patients exhibit a plethora of myopathy associated symptoms 
including facial weakness with ptosis, hypotonia, small stature, scoliosis, cleft palate, and 
susceptibility to malignant hyperthermia (Grzybowski et al., 2017; Stamm et al., 2008; Telegrafi 
et al., 2017; Zaharieva et al., 2014). Current treatment strategies focus on early diagnosis and 
symptom management particularly anticipatory management of malignant hyperthermia.  Novel 
small molecule agents that reverse pathogenesis are highly desired.  
Our analysis reveals that disease-associated stac3 variants weaken binding to the CT 
resulting in variably diminished CaV1.1 surface-membrane trafficking, highlighting potential 
pathogenic mechanisms. Indeed, reconstitution of myopathy-associated mutant stac3 (W[284]S) 
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in stac3-/- knockout zebrafish and mouse models led to diminished trafficking, triadic organization, 
and activity of CaV1.1 resulting in marked loss of EC coupling (Linsley et al., 2017a; Linsley et 
al., 2017b; Polster et al., 2016). As patients are either homozygous or compound heterozygous for 
stac mutations, it is likely that the weakened affinity of stac3 for CaV1.1 CT results in incomplete 
saturation of CaV1.1 by this regulatory protein. Our findings point to three distinct avenues for 
developing effective pharmacological strategies. First, given that CaM can both partially rescue 
reduced CaV1.1 trafficking and can enhance CaV1.1 activation gating, local enrichment of CaM 
may be an effective strategy for reversing the pathophysiology of stac3-associated myopathies. In 
this regard, a CRISPR-interference approach was recently developed to selectively manipulate 
CaM expression for a subset of cardiac arrhythmogenic long-QT syndrome (Limpitikul et al., 
2017). Second, as we identify CaV1.1 CT as the primary effector interface for stac3, FRET 2-
hybrid binding assay may be repurposed to devise high-throughput screens for small-molecule 
modulators that enhance this interaction and tune skeletal muscle function (Janzen, 2014). Third, 
more tangibly, our findings demonstrate that certain CaV channel antagonists such as diltiazem and 
verapamil may partially rescue these trafficking defects although this effect is contingent upon 
continual exposure to the drug. Diltiazem and verapamil are clinically prescribed for various 
diseases and symptoms including hypertension, arrhythmias, angina, and cluster headaches. Side-
effects observed include headaches, hypotension, gingival hyperplasia, constipation, and edema. 
Consequently, we show that low therapeutic plasma concentration is sufficient for strikingly 
enhanced surface-membrane trafficking of CaV1.1 and gating charge movement remains 
unimpaired. Fortunately, as EC coupling in skeletal muscle does not depend on freely-diffusing 
Ca2+ ions, blockade of Ca2+-influx resulting from CaV antagonists may not significantly alter the 
strength of EC coupling (Dayal et al., 2017). In fact, recent studies have shown that verapamil can 
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paradoxically potentiate contractions in mouse skeletal muscle (Dayal et al., 2017). Accordingly, 
verapamil, diltiazem, or related small-molecules may hold therapeutic potential and our 
quantitative flow-cytometric assay promises to aid the discovery of such trafficking modulators. 
Indeed, similar pharmacological chaperones have emerged as a potential therapeutic avenue for 
rescue of trafficking deficits associated with cystic fibrosis (Hanrahan et al., 2013), congenital 
hyperinsulinism of infancy (Martin et al., 2013), and Brugada syndrome (Moreau et al., 2012; 
Valdivia et al., 2004). 
Advent of selective allosteric regulators – After we demonstrated stac’s ability to increase 
PO of CaV1.1, we found that stac exerts the same effect on all members of the CaV1 family. 
Remarkably, stac is able to selectively distinguish between CaV1 and CaV2 members as well as 
NaV1.4, which share much sequence homology in their CI regions. As it turns out, hints of this 
idea of allosterically regulating ion channels may have begun many years ago. We mentioned 
previous work on CABPs and their mixed allostery model (Yang et al., 2014b). Similar to stac, 
CABPs bind to the upstream preIQ region of the CI and selectively suppress CDI of CaV1 
compared to CaV2. In fact, another structurally unrelated protein, fibroblast growth factor 
homologous factors (fhf), interacts with the NaV CI module in close proximity to the CaM binding 
interface suggesting interplay between these modulatory agents (Wang et al., 2012; Wang et al., 
2011). Like stac and CaV1, fhf may override CaM-dependent changes to NaV. Indeed, we have 
found that while fhf abolishes CDI of NaV1.4, it does not perturb CDI of CaV1 (data not shown). 
Given these similarities in mechanism, we can now harness the parallel nature of allosteric 
regulation of NaV1.4 by fhf and CaV1 by stac to glean a structural understanding. Crystal structures 
show that CaM undergoes a profound Ca2+-dependent rearrangement even when fhf binds to the 
CI of NaV1.4 (Wang et al., 2012; Wang et al., 2014) suggesting that fhf does not explicitly prevent 
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either Ca2+ binding to CaM or Ca2+/CaM interaction with effector interfaces (Gabelli et al., 2014; 
Wang et al., 2012) (Figure 5.2A). In addition, as both structures of the preIQ region are available 
for CaV1.1 and NaV1.4, we can overlay them to reveal structural differences. Fascinatingly, it 
becomes apparent that the preIQ region of CaV1.1 is dramatically different from NaV1.4 and is 
sterically incompatible for fhf docking (Figure 5.2B-D). This allosteric mechanism may constitute 
an orthogonal dimension by selectively abolishing Ca2+-feedback to ion channels (Figure 5.3). 
Beyond natural mechanisms that tune CaM signaling, these results also hint at the 
possibility of engineering synthetic regulatory pathways that specifically shunt Ca2+-signaling. 
With these distinct structural binding interfaces, emerging protein engineering methods may be 
used to attain synthetic modulation of related ion channel families especially in segments 
possessing less sequence homology. Indeed, we have found that custom allosteric sites may be 
engineered into preIQ segments (data not shown). Thus, a specialized library of synthetic 
regulators may be developed to combinatorially modify kinetic properties of CaV1 and CaV2 
channels with spatiotemporal specificity.  
In all, this work unveils stac as a novel regulator of CaV1 CaM feedback and proposes that 
generalizing this allosteric mechanism to other targets may lead to the development of new tools 






Figure 5.1. Ca2+-CaM and stac regulation is preserved in CaV1.1 CI. 








Figure 5.2. Structure insights on specificity of allosteric mechanism to abrogate Ca2+-feedback. 
(A) Structural comparison of NaV1.5 CI (green) in the presence of CaM alone (cyan, left) or both 
CaM (cyan) and fhf1b (purple). Fhf binding changes baseline conformation of CaM on NaV1 CI. 
(B) Structure of CaV1.1 upstream CI elements (blue) composed of dual vestigial EF hands and 
preIQ segments isolated from cryo-EM structure of CaV1.1 (PDBID, 5GJV). This domain is 
primary interface for stac interaction in the CaV1 CI. 
(C) Structural overlay of upstream CI elements of CaV1.1 (PDBID, 5GJV) and NaV1.5 (PDBID, 
4DCK) shows a highly conserved dual vestigial EF hand segments while the fhf binding site is 
structurally divergent. 
(D) The divergence in the fhf binding interface in CaV1.1 in comparison to NaV1.5 would introduce 






Figure 5.3. Cartoon summarizes selective modulation of Ca2+/CaM signaling to CaV1, and NaV1 
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